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Suppose the following patient visits the psychiatrist. 
Miss C, 34 years old, has suffered her third depressive episode. The first was at the age of 
22, and the second at age 31, but this is the first time she has sought medical help. Her 
mother experienced depression at age 40. Following treatment with the antidepressant 
escitalopram, Miss C recovers but still experiences mild insomnia and difficulties with 
concentration. Both the patient and psychiatrist are glad that the depression is in remission. 
She asks the psychiatrist about the chances for recurrence. This is a basic question in 
everyday practice, but is it possible to predict recurrence? What are the main risk factors 
and can patients with a high level of risk be identified? This thesis attempts to provide 
answers to these questions.
 
1.1.  Burden of depression
Unipolar major depressive disorder (MDD) is a highly prevalent condition associated with 
a high level of disability. In the ten high­income countries participating in the World 
Mental Health Survey Initiative, the average lifetime and 12­month prevalence of MDD 
was estimated at 14.6% and 5.5%, respectively (Bromet et al., 2011). In the Dutch population, 
the lifetime and 12­month prevalence of MDD is estimated at 18.7% and 5.2%, respectively 
(de Graaf et al., 2012). Despite effective treatment strategies for MDD (Vöhringer et al., 
2011), its prevalence has not fallen in recent years (de Graaf et al., 2012). Rather, the disease 
burden is expected to worsen (WHO, 2008). Currently, depression is one of the leading 
causes of sickness leave (de Graaf et al., 2012) and years lost to disability (WHO, 2001). By 
2020, depression is projected to rank second in terms of disability­adjusted life years 
(DALYs) calculated for all ages and both sexes, and this is already the case for the 15­44 
age­group (WHO, 2008). The burden is partly explained by the course of the disease, as 
recurrence and chronicity are common (Keller et al, 1992; Spijker et al, 2002). Health 
economic studies show that prevention of recurrence is likely to be effective in reducing 
the population burden of MDD (Vos et al., 2004). Psychological interventions (number 
needed to treat (NNT=5)) and maintenance treatment with antidepressants (NNT=13) are 
effective in preventing recurrence of MDD (Biesheuvel­Leliefeld et al., 2014). It remains to 
be seen which subjects are prone to recurrence and should be advised to undergo such 
therapies. 
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1.2.  Historical overview
 
The importance of describing the course of psychiatric disorders in a systematic manner 
was first highlighted by Kahlbaum (1874) and further applied in research by Kraeplin (1899). 
Kraeplin described an average duration of two to three months of depressive episodes in 
bipolar disorder and nine to twelve months in depressive disorder with a minority of 
patients with MDD experiencing a chronic course of melancholic symptoms for more 
than two years (Kraeplin, 1899). This pioneering work set the stage for research on the 
course of affective disorders (Angst, 2002). The course of depressive disorder was, in 
Kraeplin’s view, influenced by external factors; he wrote: 
‘The attacks of depressive or manic-depressive illness begin not infrequently after the illness 
or death of near relatives. In spite of the removal of the discharging cause, the attack follows 
its independent development. But, finally, the appearance of wholly similar attacks on 
wholly dissimilar occasions or quite without external occasion shows that even if there has 
been external influence, it must not be regarded as a necessary presupposition for the 
appearance of the attack’ (Kraeplin 1899).  
Anecdotally, in 1921 Kraeplin reported on a patient with depression related to the death of 
her husband. A second episode occurred after the death of her dog and a subsequent 
episode following the death of her pigeon. This anecdote is in correspondence with the 
theory later formulated by Post (1992). This theory holds that less severe life events could 
provoke a depression in those with multiple episodes of depression in the past. According to 
Post, the course of the condition is influenced by both sensitization to stressors, i.e. increased 
sensitivity to psychosocial stressors, and episode sensitization, i.e. increased vulnerability 
to recurrence with shorter intervals of remission as a function of the number of episodes. 
Both mechanisms could affect the level of gene expression of neurotransmitters, receptors 
and neuropeptides in the long term. Thus, both stressors and episodes may leave residual 
traces and vulnerabilities to further occurrences of affective illness. This suggests that the 
biochemical and anatomical substrates underlying affective disorders evolve over time as a 
function of recurrences. Research prior to 1970 postulated that depression was a relatively 
benign disorder with occasional recurrences. After 1970, long­term longitudinal studies 
found that the course of depression was more unfavourable than previously understood 
(Paykel, 1994). As a result, the perception of major depressive disorder shifted from that of 
an acute disorder to a chronic disorder. Nowadays, the course of depressive disorder is 
described as a highly variable continuum of depressive symptomatology (Judd et al., 1998; 
Spijker et al., 2002). 
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1.3.  Recurrence of MDD
Approximately 50% of the subjects who recover from an initial depressive episode will 
experience one or more additional episodes (Kupfer et al., 1996; Post, 1992). The risk of 
further episodes increases with each new episode: two major depressive episodes (MDEs) 
confers a 70% risk of a third, while three MDEs confer a 90% risk of a fourth (APA, 2000). 
Over a lifetime, the average number of major depressive episodes ranges between four 
and eight episodes and a considerable amount of time may pass between episodes 
(Keller et al, 1996). Although many studies have been published on the recurrence of MDD, 
it is difficult to compare the results due to differences in definitions of recurrence. In order 
to provide a clear definition, Frank et al. (1991) suggested describing the course of 
depression in terms of the 5 R’s: response, remission, recovery, relapse, and recurrence (Fig. 1). 
Response is defined as a significant improvement of symptoms after starting treatment 
and is often operationalized as an improvement of symptoms of more than 50% on the 
Hamilton Rating Scale for Depression (HRSD). The patient is deemed to be in remission 
when there are no symptoms or minimal symptoms of depression operationalized as a 
score on the HRSD of 8 points or lower. Recovery may be reached after remission when 
the patient has no symptoms of MDD within a fixed period. Previous research did not set 
a strict fixed period for remission. For example, one of the most important studies on the 
course of depression, the Collaborative Study of the Psychobiology of Depression (CDS) 
by the National Institute for Mental Health (NIHM) (Mueller et al., 1999) defined remission 
as minimal or no symptoms for two consecutive months. Other studies used other 
Figure 1   Course of major depressive disorder
Derived from Kupfer et al., 1991
Symptoms Remission
X X
X
Recovery
Symptoms
Depressive
Treatment phases Acute Continuation
6 months
Maintenance
“Normalcy”
Response
Relapse Recurrence
12
Chapter 1
definitions for remission and recovery and are therefore difficult to compare (Thase, 1999). 
Furthermore, the classification has not been validated (Riso et al., 1997; Furakawa et al., 
2008). Furakawa et al. (2008) recommended 4 or 6 months of remission. Relapse is defined 
as a return of symptoms during remission, and recurrence as a return of symptoms after 
recovery. 
1.4.  Predictors of recurrence 
Knowledge of recurrence of MDD and its predictors is of major importance for treatment 
decisions. Predicting MDD recurrence is a complex task because many interacting factors 
are involved. Over the past 20­30 years, a number of studies have assessed putative 
predictors for MDD recurrence. The factors considered include demographic variables 
(such as age, sex, and level of education), psychosocial characteristics (such as personality 
and social support), clinical characteristics of the depressive disorder (such as the severity 
and duration of the index episode) and biological parameters (HPA­axis, genetics). 
Predictors are frequently modelled in the dynamic stress vulnerability model (Ormel et al., 
2001). An adapted version is presented in Fig. 2. According to this model, biological factors, 
clinical features, psychosocial factors and life events interact to generate a depressive 
Figure 2   Adapted version of the dynamic stress vulnerability model
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• (Epi) Genetics
• Severity previous 
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• Number of 
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state. Fluctuations in symptom levels may be caused by stressors and could depend on 
individual coping skills. In this model, stressors are seen as predisposing factors in depression 
(first or recurrent episodes). 
1.5.  Predictors of recurrence across care settings 
A small number of review studies have described the recurrence rate and predictors of 
recurrence (Zis & Goodwin 1979; Lavori et al., 1984; Belsher & Costello 1988; Piccinelli et al. 
1994; van Weel­Baumgarten et al., 2000; Burcusa & Iacono, 2007). These reviews mainly 
focused on patients treated in specialized mental health care and did not use strict 
selection criteria. The focus on specialized care settings (with more severe, complex, 
recurrent and long­term disorders) constitutes a major limitation to current knowledge on 
predictors of recurrence, whereas the natural course of depressive disorders and the risk 
factors for recurrence are best studied using a general population sample free from 
selection bias (Eaton et al., 2008). Moreover, as most depressed patients are treated in 
primary care, risk factors for recurrence in specialized mental health care may differ from 
those in primary care. Research on the recurrence rate and risk factors in primary care 
versus specialized mental health care is still sparse.  
1.6.  Stressors, HPA-axis and recurrence
Stressors are thought to play an important role in the pathogenesis and recurrence of 
MDD (Burcusa et al., 2007; Ten Doesschate et al., 2010; Hovens et al., 2012). It seems likely 
that individual vulnerability to stress is key to the development of depression and 
subsequent recurrence, since stressful events do not automatically result in depression (de 
Kloet et al., 1998; de Kloet et al.,  2005). The neuroendocrine response to stress includes the 
activation of the sympathetic nervous system and the release of cortisol from the adrenal 
glands mediated by the hypothalamic­pituitary­adrenal (HPA) axis (Fig. 3) (Pariante & 
Lightman 2008). 
Cortisol affects various systems in the body, including the HPA axis itself, the cardiovascular 
system, the immune system, metabolism, and cell growth. Levels of cortisol are high upon 
awakening, increase 50­60% in the first 30­40 minutes thereafter (known as the cortisol 
awakening response), drop quickly in the subsequent few hours and slowly decline to 
reach the lowest point near midnight (Pruessner et al., 2007). Although the HPA­axis has 
been studied extensively during depression (Stetler et al., 2011), and alternations to the 
HPA­axis has been reported to be one of the most consistent findings in psychiatry 
(Pariante et al., 2008), there is no consensus as to whether HPA­axis alternations have a 
predictive value for recurrence of MDD. 
14
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1.7.  Genetic factors associated with recurrence
The effects exerted by cortisol are mediated by two brain corticosteroid receptor types, 
the mineralocorticoid receptor (MR), with a high affinity already occupied under basal 
conditions and the glucocorticoid receptor (GR), with a low affinity and activated 
predominantly under stress (Fig. 3). Response to stress is influenced by genetic factors 
(Wϋst et al., 2004); the availability and efficiency of corticoid receptors are influenced 
by variation in the genes coding for them. Small variants, called single nucleotide 
polymorphisms (SNPs) are commonly present in the GR and MR receptor gene and 
genetic variation within the GR and MR produces differences in receptor function (Stevens 
et al., 2004). The GR gene (NR3C1) is located on chromosome 5 and the MR gene (NR3C2) 
is located on chromosome 4. Associations have been found between a number of SNPs 
and depression (v. Rossum et al., 2006; v. West et al., 2006). It has also been postulated that 
certain SNPs, which are associated with glucocorticoid sensitivity could be the weak link 
in the pathogenesis of depression (Pariante et al., 2008) but it is not known whether these 
SNPs are also associated with recurrence of MDD. 
Figure 3   The hypothalamic­pituitary­adrenal axis. Schematic diagram of the hypo ­
thalamic­pituitary­adrenal (HPA) axis
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Hypothalamus
Anterior Pituitary
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Parvocellular neurons from the 
hypothalamus release corticotropin­
releasing hormone (CRH) and arginine 
vasopressin (AVP) which stimulate 
adrenocorticotropic hormone (ACTH) 
secretion from the anterior pituitary. 
ACTH stimulates the release of cortisol 
from the adrenal cortex, which has a 
number of biological functions involved 
in the stress response. Cortisol exerts 
negative feedback on the hypothalamus, 
anterior pituitary and most importantly 
via the hippocampus. 
GR=glucocorticoid receptor; 
MR=mineralocorticoid receptor. 
GR=glucocorticoid, 
MR=mineralocorticoid, 
ACTH=adrenocorticotropic hormone, 
CRH=corticotropin releasing hormone, 
AVP=arginine vasopressin. 
Derived from Claire Abou-Seif et al., 2012.
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1.8.  Datasets
For this thesis, data were derived from the Netherlands Mental Health Survey and 
Incidence Study (NEMESIS) (Bijl et al., 1998a) and the Netherlands Study of Depression and 
Anxiety (NESDA) (Penninx et al., 2008). NEMESIS is a prospective naturalistic psychiatric 
survey among the Dutch adult general population (aged 18­64) with 7076 persons 
recruited at baseline. Data were recorded in three waves: at baseline in 1996, at 12­month 
follow­up in 1997 and after three years (1999). NESDA is an ongoing longitudinal cohort 
study, launched in 2004, which examines the long­term course of depressive and anxiety 
disorders in various health care settings. The NESDA cohort (N=2981) consists of 
respondents (18­65 years) with (i) a current anxiety and/or depressive disorder, (ii) a prior 
history of a depressive and/or anxiety disorder and (iii) healthy controls. All respondents 
were administered a baseline assessment, which included psychopathology, demographic 
and personal characteristics, psychosocial functioning, and biomarkers. Respondents 
were recruited in primary care through a screening procedure, in specialized mental 
health care when newly enrolled and in the community.  
1.9.  Aims and outline of the thesis
The objectives of this thesis are to examine the risk of recurrence of major depressive 
disorder across care settings and to study its predictors and the way they interact. On the 
basis of this knowledge, it might be possible to distinguish subjects at high risk for 
recurrence of MDD from those at low risk. Accurate identification of these groups may 
help to improve both the efficacy and efficiency of mental health care. 
This thesis is divided into seven chapters. Following an introduction (Chapter 1), Chapter 2 
gives an overview of previous research on prevalence and predictors of MDD recurrence. 
In Chapter 3, the incidence and predictors of MDD recurrence in the general Dutch adult 
population are investigated based on NEMESIS data. In Chapter 4, predictors of recurrence 
are analysed across treatment settings. Chapter 5 examines HPA­axis alterations as a 
predictor of recurrence and the glucocorticoid and mineralocorticoid receptor poly­ 
morphism associated with recurrence of MDD are examined in Chapter 6. Chapters four 
through six are based on NESDA data. In Chapter 7 the results of the studies are summarized 
and discussed. The studies are summarized in Figure 4 (mind map). 
16
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Figure 4   Overview of studies in this thesis
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Prevalence and predictors of 
recurrence of major depressive disorder 
in the adult population
F. Hardeveld, J. Spijker, R. de Graaf, W.A. Nolen, A.T.F. Beekman.
Acta Scandinavica Psychiatrica. 2010:122(3);184-191.
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Abstract
Objective: Knowledge of the risk of recurrence after recovery of a major depressive 
disorder (MDD) is of clinical and scientific importance. The purpose of this paper is to 
provide a systematic review of the prevalence and predictors of recurrence of MDD.
Method: Studies were searched in Medline en PsychINFO using the search terms ‘recur*’, 
‘relaps*’, ‘depress*’, ‘predict*’ and course. 
Results: Recurrence of major depressive disorder in specialised mental health care 
settings is high (60% after 5 years, 67% after 10 years and 85% after 15 years) and seems 
lower in the general population (35% after 15 years). Number of previous episodes and 
subclinical residual symptoms appear to be the most important predictors. Gender, civil 
status, and socioeconomic status seem not related to the recurrence of MDD.
Conclusion: Clinical factors seem the most important predictors of recurrence. Data from 
studies performed in the general population and primary care on the recurrent course of 
major depressive disorder are scarce. 
21
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2.1.  Introduction
Major depressive disorder (MDD) is one of the most prevalent mental disorders with a 
high morbidity. The lifetime prevalence in the United States of America (US) is estimated 
at 16.2% (Kessler et al., 2003). Currently, MDD is worldwide the third leading cause of 
burden of disease and will rise to the first place in 2030 (WHO, 2008). 
 Long­term studies performed in the US (Keller et al., 1982) showed that MDD has a 
less favourable course than initially thought. Knowledge about the course of MDD and its 
determinants is of clinical and scientific importance. It would seem reasonable to treat 
patients with a high risk of recurrences as a chronic disorder (Andrews, 2001), while 
treatment of those with a low risk of recurrence may be limited to the index episode. 
Accurate differentiation of these groups may help to improve both the efficacy and the 
efficiency of mental health care. The treatment of the high risk group should not only 
include maintenance treatment with antidepressants, but also aim for the reduction of risk 
factors for recurrence. This approach has been successful in other disciplines in medicine. 
The prevention of myocardial infarction for example targets its risk factors (e.g. smoking, 
high blood pressure, and hypercholesterolemia) and this approach has lowered the 
incidence of myocardial infarction (Pais, 2006). Moreover, prevention programmes for 
diabetes have been successful in the prevention of the long­term complications, such as 
reducing diabetic retinopathy and nephropathy (Nathan, 1998). Identification of predictors 
of recurrence can help to select which patients should be offered longer term preventive 
care. Furthermore, it is likely that patients treated in specialised mental health care have a 
higher risk for recurrence than patients treated in primary care. If proven true, this would 
lead to different recommendations for patients treated for MDD in specialised mental 
health care vs. primary care. 
 Over the past 20­30 years several studies have been able to assess putative risk factors 
for recurrence of MDD. The factors that have been considered include demographic data 
(such as age, sex, and level of education), psychosocial characteristics (such as personality 
and social support) and clinical characteristics of the depressive disorder (such as the 
severity and duration of the index episode). 
Aims of the study
To perform a systematic review of prevalence and risk factors predicting recurrence of 
MDD, comparing patients in specialised mental health with those seen in primary care 
and community settings. 
22
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2.2.  Material and Methods
Relevant articles were searched in PsychINFO and Medline with the search terms ‘recur*’, 
‘relaps*’, ‘depress*’, ‘predict*’, and course. The flow chart is shown in Fig. 1. 
Only articles written in English which studied the adult population and which were 
published between January 1980 and August 2008 were included (n = 736). These articles 
were screened on relevance, methodology, and study population by the first author (FH), 
using the title and summary. Ninety­nine articles were retrieved for further evaluation. 
Another three articles were included after examining the references. Of these 102 articles 
two authors (FH & JS) studied the full text. The following selection criteria were applied: i) 
naturalistic cohort study, ii) including subjects with MDD, iii) MDD diagnosed using a 
diagnostic interview or checklist based on Research Diagnostic Criteria/Bedford College 
Criteria (RDC/BCC) criteria, DSM III/III­R/DSM IV criteria or ICD­9/10 criteria, iv) the course 
had to be measured with a standardised instrument or checklist, v) with a minimum 
follow­up of six months, vi) and including at least 50 subjects. Moreover, vii) the criteria of 
Figure 1   Flow chart of selection of studies that researched the prevalence and predictors 
of recurrence of MDD
Potential relevant studies: 736
Medline: 675
PsychINFO: 208 
Potential relevant studies screened 
on title and abstract (n = 736)   
Retrieved for further evaluation
(n = 99)
3 crossreferences
Included in review (n = 27)
Excluded studies (n= 637)
• methodology (n= 36)
• patient population (n= 122)
• diagnosis MDD (n= 94)
• no predictor measured (n= 215)
• no recurrence measured (n= 170)
Excluded studies (n= 74)
• time to recurrence was not
measured properly (n= 31)
• no diagnostic instrument used  (n=21)
• patient population (n= 12)
• no predictor measured (n= 4)
• follow-up < 6 months (n=2)
• no naturalistic cohort study (n=5) 
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remission, recovery, relapse and recurrence according to Frank et al. (1991) had to be 
applied; relapse is a return of symptoms satisfying the full syndrome criteria for an episode 
that occurs during the period of remission but before recovery, recurrence is the 
appearance of a new episode of major depressive disorder and can occur only during a 
recovery, remission is a period during which an improvement of sufficient magnitude is 
observed that the individual no longer meets syndromal criteria for the disorder, recovery 
is a remission that lasts for X days or longer. Frank et al. (1991) did not formulate the time 
to recovery but made suggestions depending on the course instrument used. All included 
studies had to fulfil all the applied selection criteria. Studies that included patients with 
bipolar disorder, depression with a seasonal pattern, postpartum depression, or specific 
age groups were excluded because this may unduly influence the risk of recurrence. We 
did not subdivide the studies according to MDD subgroups (e.g. melancholic, with 
psychotic features, catatonic, atypical) because too few studies differentiated according to 
subgroups and in those who did the subgroups were usually too small to compare. The 
articles were screened independently on the selection criteria by FH & JS.  When there 
were inconsistencies (n=3) both reviewers reached consensus by analysing the articles on 
the applied selection criteria together. 
2.3.  Results
Twenty­seven studies were included for further evaluation. The articles were subdivided 
in studies that included patients from the general population, primary care, and specialised 
mental health care. The characteristics of the included studies are summarised in Table 1.
Prevalence 
The prevalence depends on the setting in which is measured. Table 2 gives an overview 
of the percentage of recurrence by setting. 
Specialised mental health care  
The majority of the available studies were carried out in specialised mental health care. 
Considering all studies, the overall risk of recurrence after recovery during the first year 
ranges between 21% and 37%. The high percentage of 37% was observed in a study that 
selected patients with a high number of previous episodes (Maj et al., 1992). The lowest 
percentage of 21% was found in a Japanese study, that included patients treated in 
specialised mental health care as well as primary care (Kanai et al., 2003). An important 
study is the National Institute of Mental Health Collaborative Program on the Psychobiology 
of Depression (CDS). In this study 431 patients with a MDD were followed 15 years, the first 
five years half yearly and then yearly. During the first year after recovery, the risk of 
recurrence was 25%, increasing to 85% over 15 years (Mueller et al., 1999). 
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Primary care and general population
Only one primary care study was included. In this study, which included 386 patients, a 
percentage of recurrence of 31% after a follow­up of one year was found (Gopinath et al., 
2007). This percentage is comparable with results from the abovementioned studies in 
specialised mental health care. We also included only one prospective population­based 
study. This is the Baltimore Epidemiologic Catchment Area follow­up (ECA) (Eaton et al., 
1997; Eaton et al., 2008) which included 78 patients at risk for a recurrence of MDD. After a 
follow­up of 15 years, the percentage of recurrence after recovery was 35%. 
Predictors 
Demographic factors
Many studies reported on the association between demographic factors and the risk of 
recurrence. These studies were mainly performed in specialised mental health care. 
Demographic factors such as gender, age, social economic status (SES) and marital status 
were not found to be related to the recurrence of MDD (Table 3). However, there are 
exceptions. Mueller et al. (1999) and Winokur et al. (1993), both part of the earlier mentioned 
CDS study, found a greater risk of recurrence among women. Mueller et al. (1999) observed 
a higher risk of recurrence among those who have never been married. And lastly, Holma 
et al. (2008) and Eaton et al. (1997) reported that a younger age was related to recurrence.
Table 2   Percentage of patients with a recurrence of MDD during follow up
Setting Author
Follow-up 
(years)
1 5 10           15 
Percentage (%) Specialised 
mental  
health care
Holma et al. 2008 ­ 70.7 ­ ­
Kanai et al. 2003 21 42 ­ ­
Maj et al. 1992 37i 75 ­ ­
Mueller et al. 1999 25 60 ­ 85
Melartin et al. 2004 38ii ­ ­ ­
Ramana et al. 1985 40iii ­ ­ ­
Solomon et al. 2000 ­ ­ 67 ­
Primary care Gopinath et al. 2007 31 ­ ­ ­
General  
population
Eaton et al. 1997 ­ ­ ­ 35
I Percentage of recurrence after 6 months is 24%. 
ii Percentage of recurrence after 1.5 years.
iii Percentage of recurrence after 15 months. 
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Table 3   Percentage of patients with a recurrence of MDD during follow up
Significant association 
between recurrence  
of MDD present
Significant association 
between recurrence  
of MDD absent
Demographic 
factors
Age 48,76 58,87,93,109,115,120, 
128,153
Female 125,201 44,48,49,76,87,93,109, 
115,120,128,153,166
Marital status 125 44,48,49,76,87,93,115, 
120,128,140,153
Low social economic 
status/educational level
­ 44,48,49,58,76,87,93, 
115,120,128,153
Life events, 
social support, 
psychosocial 
impairment, 
and personality 
factors
Severe life event before 
depressive episode
­ 76,120,140
Lack of social support ­ 49,76,120,140 
Decreased psychosocial 
functioning
58,169 ­
Comorbid personality 
disorder
81 76,120,153
Neuroticism 58 76,120
Coping skills 58,44 ­
Clinical factors Number of previous 
episodes
44,58,83,109,115,125, 
142,168,201
76,81,87,93,120,128,153
Subclinical residual 
symptoms
83,84,87,139,141,142 81,94,120
Age of onset 49,142,201 76,94,109,115,120,153
Severity of the last 
 episode
58,76,81,93,120,142,153 48,115,153,166
Duration of last episode 109,125 76,87,115,120,153
Comorbid psychiatric 
disorder
76,91,115,120 81,87,109
Family history of MDD 115 49,87,93,128,153,201
Each row represents the studies that performed research on the specific predictor in relation to recurrence of 
MDD. The figures refer to the literature in the reference list. 
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Life events, social support, impairment of psychosocial functioning and 
personality factors
The included studies (Holma et al., 2008; Melartin et al., 2004; Paykel et al., 1996) reported 
that a severe life event and lack of social support were not related to recurrence. Patients 
with impaired functioning in areas such as work, relationships, and leisure after (complete) 
remission appear to have a higher risk for recurrence of a MDD (Gopinath et al., 2007; 
Solomon et al., 2004). A personality disorder can be a predictor for recurrence (Ilardi et al., 
1997). In a study with 50 patients who were followed 33 to 84 months, both cluster B and C 
personality characteristics were related to a higher risk for recurrence. There are, however, 
also studies which observed no such association (Holma et al., 2008; Melartin et al., 2004; 
Ramana et al., 1995). Patients with a high neuroticism score could also have a high risk for 
recurrence (Gopinath et al., 2007). However, Holma et al. (2008) observed no such association. 
Furthermore, it is possible that coping skills are associated with risk for a recurrence of 
MDD. In a study among 110 patients in a primary care population, patients with moderate 
coping skills had a shorter time to recurrence in comparison to those with better skills 
(Conradi et al., 2008). In agreement with this result, patients with lower self­efficacy had a 
higher risk for recurrence (Gopinath et al., 2007). 
Clinical factors
Numerous clinical variables have been studied in relation to the recurrence of MDD (Table 3). 
The main variables are age of onset of the first depressive episode, duration and severity 
of the last episode, the number of previous episodes, the presence of comorbid axis I 
disorders, subclinical residual symptoms and a family history of MDD. One of the variables 
that seems associated with the recurrence of MDD is the number of previous episodes. 
A larger number of included studies (Kanai et al., 2003; Mueller et al., 1999; Gopinath et al., 
2007; Winokur et al., 1993; Conradi et al., 2008; Judd et al., 1998; Lavori et al., 1994; Pintor 
et al., 2004;  Solomon et al., 2000), mainly performed in specialised mental health care, 
found an association between the number of previous episodes and the risk of recurrence. 
Within these studies are CDS studies (Mueller et al., 1999; Winokur et al., 1993; Judd et al., 
1998; Lavori et al., 1994; Solomon et al., 2000) which included a high number of patients 
with a long follow­up using the life chart method. There are, however, also some studies 
that did not find an association (Kanai et al., 2003; Holma et al., 2008; Melartin et al., 2004; 
Ilardi et al., 1997; Ramana et al., 1995; Kennedy et al., 2003; Naz et al., 2007), but most of 
these studies included smaller numbers of patients at risk (Kanai et al., 2003; Ilardi et al., 
1997; Ramana et al., 1995; Kennedy et al., 2003; Naz et al., 2007) or did not use the life chart 
method (Ramana et al., 1995; Naz et al., 2007). The association between number of previous 
episodes and recurrence of MDD seems strong, the odds ratio is estimated at 1.64 (Judd 
et al., 1998). Another strong predictor for recurrence of MDD seems to be the presence of 
subclinical residual symptoms. Also, a larger number of included studies found an 
association between this predictor and the risk of recurrence (Kanai et al., 2003; Judd et al., 
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1998; Pintor et al., 2004; Judd et al., 2000; Paykel et al., 1995; Pintor et al., 2003) and the 
included studies had a long follow­up using the life chart method (Judd et al., 1998; Judd 
et al., 2000). The included studies suggest that this is the strongest predictor for a 
recurrence. Judd et al. (1998) described that patients with residual subclinical symptoms 
after recovery of MDD relapsed three times faster than an asymptomatic group (median 
68 vs. 23 weeks) and found an odds ratio of 3.65 for residual symptoms. Three included 
studies did not find an association. However, the study by Iliadi et al. (1997) included a 
relatively small number of patients (n=50) and Melartin et al. (2004) did find a bivariate 
association with an high odds ratio of 2.12 but in the multivariate models it was not 
significant anymore (Melartin et al., 2004). 
 Nonetheless, although there is strong evidence that subclinical residual symptoms 
are a predictor for a shorter time to recurrence, this does not imply that in the long run the 
overall risk of recurrence necessarily differs. Kennedy et al. (2004) reported in a study 
population of 60 patients with recurrent depression and residual symptoms a percentage 
of recurrence of 42% after one year and 56% after two years in comparison with respectively 
20% and 42% in the group without residual symptoms. After a follow­up of 8­10 years, the 
percentage of recurrence between the groups was no longer significantly different (74% 
in the group with subclinical residual symptoms and 70% in the group without residual 
symptoms). One of the major limitations in this study was the use of a single longitudinal 
interview to cover the long follow­up period of 8­10 years. Studies that assessed the 
association between age of onset of the first depressive episode and the risk of recurrence 
are inconsistent. For example, Eaton et al. (2008) observed that a younger age of onset was 
a significant predictor of time to recurrence, with each additional year of age at onset 
lowering the risk for recurrence by 0.96 (95% confidence interval 0.93­0.99), but this result 
was not corroborated in other studies (Maj et al., 1992; Lavori et al., 1994). There is also 
inconclusive data that severity or duration of the last episode is a risk factor for recurrence. 
A high number of included studies found an association between severity and risk of 
recurrence of MDD (Gopiath et al., 2007; Holma et al., 2008; Melartin et al., 2004; Ilardi et al., 
1997; Ramana et al., 1995; Pintor et al., 2004; Kennedy et al., 2003) but the studies that did 
not find an association also included CDS studies (Mueller et al., 1999; Lavori et al., 1994). 
The opposite seems true for duration of the last episode; a high number of these studies 
did not find an association (Maj et al., 1992; Kanai et al., 2003; Holma et al., 2008; Melartin et 
al., 2004; Ramana et al., 1995), but the CDS studies did (Mueller et al., 1999; Lavori et al., 
1994). Comorbid axis I disorders seems to increase the risk for recurrence (Melartin et al., 
2004). This is shown for dysthymia (Maj et al., 1992, Keller et al., 1983) and for social phobia 
(Holma et al., 2008). A family history of MDD did have an association with recurrence in 
one study (Maj et al., 1992) but this could not be corroborated in a number of other studies 
(Kanai et al., 2003; Eaton et al., 2008;Winokur et al., 1993; Ramana et al., 1995; Kennedy et al., 
2003; Naz et al., 2007). 
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2.4.  Discussion
To our knowledge, this is the first systematic review which outlines the prevalence and 
predictors of recurrence after remission of an episode of MDD. Several conclusions can be 
drawn from the selected studies. i) The percentage of recurrence in the specialised mental 
health care is very high (up to 85% after 15 years) and in this population it is better to ask 
when instead of whether the patient will have a recurrence. ii) The included study suggest 
that the percentage of recurrence in the primary care population is similar. iii) The 
percentage of recurrence in the general population is lower (up to 35% after 15 years). iv) 
Two main predictors of recurrence can be identified: the number of previous episodes 
and subclinical residual symptoms after recovery for the last episode. Demographic 
factors such as gender, SES, and civil status, which are risk factors for the onset of the first 
depressive episode (Anthony et al., 1991; De Graaf et al., 2002), do not appear to predict 
recurrence after recovery. The age of the index episode also does not seem to predict 
recurrence. The evidence is (still) inconclusive for the following predictors: neuroticism, 
lack of social support, severe life event, the presence of a comorbid axis I and II disorder, 
the severity and duration of the previous episode, a younger age of onset, a family history 
of MDD and psychosocial impairment after a depressive episode. The severity of the 
previous episode and psychosocial impairment after a depressive episode seem most 
likely associated, whereas a family history of MDD, lack of social support and duration of 
the previous episode seem less likely predictors of recurrence. 
 Our review has several limitations. Firstly, despite the use of strict selection criteria, 
the included studies remain difficult to compare. This is also the reason why we did not 
perform a formal meta­analysis, pooling the results. The studies used different diagnostic 
and course instruments and the duration of follow­up varied between the studies. Our 
conclusions are therefore not based on a strong evidence based method but merely on 
number of studies with a significant association and design of the study (number of 
patient included, course instrument). However, other not included but well performed 
studies show similar results (Kessing et al., 2000; Kessing et al., 2004). These studies were 
not included because the data did relate to readmissions because of MDD and not to 
recurrence. Furthermore, in a number of studies the difference between a relapse and a 
recurrence of MDD could not be fully specified because these studies also included 
patients with partial remission. Subclinical residual symptoms can also be seen as a limited 
prolongation of an active disease process and is therefore a difficult predictor to interpret 
in relation to recurrence.  Moreover, selection of specific patient samples probably 
influenced the outcome. For instance, in the CDS study patients were all referrals to a 
tertiary care centre (Mueller et al., 1999; Solomon et al., 2000), while in other studies only 
patients with already recurrent MDD were included (Maj et al., 1992; Gopinath et al., 2007). 
It is likely that this would lead to a higher risk of recurrence. Furthermore, this review only 
included naturalistic studies, thus treatment is a factor that was not controlled for. Patients 
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receiving more vigorous or more extended treatment would be less likely to recur. As 
more vigorous or extended treatment is more likely in tertiary care centers, this would 
offset the previous effect of selection. Finally, the number of well carried out studies in 
primary care and in the general population is limited. Therefore, no clear conclusions can 
be drawn on the prevalence and predictors of recurrence in these settings; the conclusion 
that prevalence of recurrence of MDD in the general population is 35% is only based on 
one study (Eaton et al., 1997). Most studies in primary care and in the general population 
did not use clear defined criteria for remission and recurrence and did not use a diagnostic 
instrument in commencement of the study. The results suggest that the percentage of 
recurrence of MDD in primary care is comparable with the specialised mental health care. 
However, the study of Gopinath et al. (2007) only included patients that experienced at 
least three depressive episodes, so this is not a representative sample. In other (not 
included) studies in primary care a lower percentage of recurrence was found. For 
example, a highly cited study is a Dutch study among 222 patients with a follow­up of ten 
years (Van Weel­Baumgarten et al., 1998). In this study a percentage of recurrence of 40% 
was found after ten years. This study was not included because the diagnosis was not 
made with a standardised instrument and the course was measured retrospectively with 
a registration system. 
In conclusion, it becomes increasingly clear that MDD (especially in the specialised mental 
health care) is often a chronic and/or recurrent disorder with consequences over the 
entire lifespan. Demographic determinants play a role in the onset of the first depressive 
episode but seem not important during the course. The risk factors for recurrency and 
chronicity of MDD seem to have similarities. For both, clinical factors seem most important. 
The knowledge that clinical variables are significant risk factors could be taken into 
account during the initial phase of the treatment. Moreover, it is possible that chronicity 
and recurrency are both expressions of the same dimension: everything what predicts 
chronicity (subclinical residual symptoms, number of previous episodes) predicts 
recurrences. With the increasing knowledge on genetic and neurobiological determinants 
of MDD it may be possible to identify better predictors of its course (Robinson et al., 2008). 
Future research should pay attention to this area. 
 What are the consequences for clinical practice? Knowledge of predictors of recurrence is 
essential for making treatment decisions. Most patients with MDD in specialised mental 
health care will have a recurrence whereas clinical variables probably determine the time 
to recurrence. It is important to closely monitor and treat patients with subclinical residual 
symptoms because these patients have a high risk of recurrence. Patients with multiple 
recurrences should receive maintenance treatment with antidepressants, with special 
attention to treatment adherence. The risk of relapse or recurrence by maintenance 
treatment with antidepressants can be reduced by 25% when compared with placebo 
(Geddes et al., 2003; Kaymaz et al., 2008). However, we do not know the efficacy of anti­
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depressants on the recurrence rate over a long period. In addition, preventive interventions 
should be considered in patients with multiple recurrences, focusing on residual sympto­ 
matology and specific coping styles (Bockting et al., 2006). Nonetheless, knowledge 
about predictors of recurrence is still incomplete and prospective research, particularly in 
the general population, is necessary to give better­founded conclusions which predictors 
play a role in recurrences. It could also be useful to take along different outcome variables 
(severity, time between recurrences, number of recurrences) because different factors 
could predict different outcome variables (Conradi et al., 2008). If we know which 
predictors play a role in recurrences and which interventions could help to prevent 
recurrences there is enough knowledge available to develop well­founded guidelines 
for treatment and recurrence prevention for the major depressive disorder. 
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Abstract
Background: Knowledge of the risk of recurrence after recovery from major depressive 
disorder (MDD) in the general population is scarce. 
Methods: Data were derived from 687 subjects in the general population with a lifetime 
DSM­III­R diagnosis of MDD but without a current major depressive episode (MDE) or 
dysthymia. Participants had to be at least 6 months in remission and were recruited from 
the Netherlands Mental Health Survey and Incidence Study (NEMESIS), using the 
Composite International Diagnostic interview (CIDI). Recency and severity of the last MDE 
were assessed retrospectively at baseline. Recurrence of MDD was measured prospectively 
during the 3­year follow­up. Kaplan­Meier survival curves were used to measure time to 
recurrence. Determinants of time to recurrence were analyzed using proportional hazard 
models.
Results: The estimated cumulative recurrence percentage of MDD was 13.2% at 5 years, 
23.2% at 10 years and 42.0% at 20 years. In bivariate analysis, the following variables 
predicted a shorter time to recurrence: younger age, younger age of onset, higher number 
of previous episodes, a severe last depressive episode, negative youth experiences, 
ongoing difficulties before recurrence and high neuroticism. Multivariably, younger age, 
higher number of previous episodes, a severe last depressive episode, negative youth 
experiences and ongoing difficulties remained significant.
Conclusions: In this community sample, the long­term risk of recurrence was high, but 
lower than that found in clinical samples. Subjects who have had a MDE have a long­term 
vulnerability for recurrence. Factors predicting recurrence included illness­ and 
stress­related factors.  
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3.1.  Introduction
Major depressive disorder (MDD) is often a chronic and/or recurrent disorder that can have 
major consequences over the entire lifespan. For clinical practice, it is important to be able 
to predict the risk of recurrence. In patients with a high risk of recurrence, it would seem 
reasonable to treat the depression as a chronic disorder (Andrews, 2001), for example with 
antidepressants as maintenance treatment (Geddes et al., 2003; Kaymaz et al., 2008); while 
treatment of those with a low risk of recurrence may be limited to the index episode. If the 
most important risk factors for recurrence are known, subgroups might be selected that 
need more intensive or long­term treatment. 
 Over the past 20­30 years, several studies have been able to assess putative risk 
factors for recurrence of MDD. The factors that have been considered include sociodemo­
graphic data (e.g. age, gender, and level of education), psychosocial characteristics (e.g. 
personality and social support) and clinical characteristics of the depressive disorder (e.g. 
the number, duration and the severity of the previous episodes). Clinical factors, such as 
subclinical residual symptoms and the number of previous episodes, have been found to 
be the most important predictors, whereas sociodemographic factors did not seem to 
predict recurrence of MDD (Hardeveld et al., 2010). However, the prediction of recurrence 
is complex; it is likely that multiple predictors can be identified and that predictors interact 
with one another producing an aversive cascade of synergetic events resulting in the 
recurrence of a depressive state. Consequently, it may be possible to identify a combination 
of risk factors that have a high overall predictive value. 
 A major limitation of the current knowledge is that majority of previous studies on 
risk factors for recurrence were performed in specialized mental health care (with more 
severe, complex, recurrent and long­lasting disorders) whereas the natural course of 
depressive disorder and the risk factors for recurrence are best studied using a general 
population sample without any selection bias (Eaton et al., 2008). Moreover, as most 
depressed patients are treated in primary care, it could be that risk factors for recurrence 
in specialized mental health care are different from those in primary care.
 Large­scale general population­based follow­up studies addressing the recurrence 
of MDD are scarce. The best­known studies are the Zurich cohort (Merikangas et al., 2003), 
the Lundby study (Mattison et al., 2007) and the Baltimore Epidemiologic Catchment Area 
(ECA) follow­up (Eaton et al., 1997; Eaton et al., 2008).These studies focused mainly on the 
risk of recurrence of MDD and not on the determinants of recurrence. Therefore, 
knowledge about the predictors of recurrence is still incomplete. 
 The aim of this study is to determine the incidence and risk factors for the recurrence 
of MDD among people who had recovered from their last episode of MDD, using data 
from the Netherlands Mental Health Survey and Incidence Study (NEMESIS), a large 
prospective naturalistic psychiatric survey (N=7076) among the general population. 
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3.2.  Method
Study sample
Data were derived from the NEMESIS (Bijl et al. 1998b), which surveyed the Dutch adult 
general population (aged 18­64). Data were recorded at three waves: at baseline in 1996, 
at the 12­month follow­up in 1997 and after 3 years (1999). The methodology is described 
in detail elsewhere (Bijl et al. 1998b). In brief, NEMESIS is based on a multistage, stratified, 
random sampling procedure. The first step of this study was to draw a sample from 90 
Dutch municipalities. The stratification criteria were urbanicity (five categories as classified 
by Statistics Netherlands) and adequate distribution over the 12 provinces. The second 
step was to draw a sample of private households (addresses) from post office registers. 
The number of households selected in each municipality was governed by the size of its 
population. The third step was to choose which individuals to interview. The selected 
households were sent a letter of introduction signed by the Minister of Public Health 
requesting their participation. Shortly thereafter, they were contacted by telephone by 
the interviewers. Households with no telephone or with ex­directory numbers (18%) were 
visited in person. A respondent was randomly selected in each household: the member 
with the most recent birthday, on the condition that they were between 18 and 64 years 
of age and sufficiently fluent in Dutch to be interviewed. Persons who were not 
immediately available (owing to circumstances such as hospitalization, travel or 
imprisonment) were contacted later in the year. If necessary, the interviewers made a 
maximum of ten phone calls or visits to an address at different times and on different days. 
Respondents received no remuneration, but only a token of appreciation at the end of the 
interview. At baseline (T0), 7076 persons were eligible for inclusion, with a response rate of 
69.7% (Bijl et al. 1998a). After 12 months (T1), 1458 respondents  (20.6%) were lost to attrition 
and, after three years (T2), a further 822 (14.6%) were lost. 4796 respondents (67.8%) were 
interviewed at all three waves. 
Cohort
We aimed to study the time to recurrence of a major depressive episode (MDE) and 
associated risk factors, in respondents who had recovered from a MDE. The design relied 
on both retrospective and prospective data. The recency and severity of the last depressive 
episode was assessed retrospectively at baseline (T0) using the Composite International 
Diagnostic Interview (CIDI); respondents were asked at what age the last period of MDD 
ended. The time to recurrence was assessed prospectively between T0 and T2.  To prevent 
contaminating the risk factor data with current levels of depression, we only included 
respondents without a current MDD and/or dysthymia at baseline (T0). Dysthymia was 
defined according to DSM­III­R criteria but we could not assess whether dysthymia was 
also present before the onset of MDD. An advantage of including people with remitted 
depression at baseline was that the measurement of the predictors was not influenced by 
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the presence of a MDE. Furthermore, respondents had to be free of these diagnoses for six 
months. As a consequence, a duration of partial or full remission of at least six consecutive 
months was chosen. This term was based on a 10­year follow­up study (Furukawa el al. 
2008) which concluded that the best duration to declare remission is probably 4 or 6 
months. Therefore, recurrence of MDD was operationalized as a return of symptoms after 
(partial or complete) remission of at least 6 months and symptoms that were sufficiently 
severe to satisfy criteria for MDD according to DSM­III­R. It is important to note that 
respondents with partial remission were also included because this is a well known risk 
factor for recurrence (Hardeveld et al. 2010). Respondents with lifetime diagnoses of 
bipolar disorder or schizophrenia or for whom the diagnosis had changed during the 
follow up period from unipolar to bipolar disorder or schizophrenia were excluded, as 
these subjects are likely to have a different recurrence risk. To contribute to the prospective 
data, respondents had to be reinterviewed at least once during follow­up. 
 Consequently, the study sample was assembled by first identifying all respondents 
with a lifetime diagnosis of MDD (first or recurrent cases) at T0 (N=1153). Three cases had 
missing data on the variable ‘age of the last depressive episode’. Of the 1150 cases 
identified, 289 respondents had an ongoing episode of MDD at T0 (6­month prevalence) 
and 17 had dysthymia at T0 (6­month prevalence), and were excluded from further 
evaluation. For eight respondents, the diagnosis had changed during the follow up period 
from unipolar to bipolar disorder or schizophrenia, and they were also excluded. Thus, 836 
respondents were at risk for a recurrent episode of MDD. Of the 836 eligible subjects, 687 
(82.2%) were re­interviewed at T1 and 590 (70.1%) at T2. Hence, 687 (82.2%) respondents 
were reinterviewed at least once and constitute the study sample (Table 1).  Drop­out 
(30.0%) of the eligible subjects was lower than that in the total sample (35.2%) and was not 
associated with demographic factors (age, gender), severity of the last episode of MDD 
(X2= 2.53, df=2, p=0.28) or number of previous episodes (X2=0.63, df=1, p=0.43). 
The sociodemographic and clinical characteristics of the study sample (n=687) were as 
follows (Table 1): 68.0% (N=467) were female; median age was 40.7 years; 73.6% (N=506) 
were married or cohabiting; 70.3% (N=483) were employed; mean age of onset was 29.9 
years (s.d.=10.5); 47.0% (N=323) had experienced a single MDE and 53.0% (N=364) had two 
or more episodes; in 31.6% (N=217)  the last MDE was severe, in 31.4% (N=216) moderate 
and in 24.3% (N=167) mild; 40.0% (N=275) had a lifetime anxiety disorder at T0; 7.6% (N=52) 
had a lifetime alcohol dependence; and 2.0% (N=14) had a lifetime drug dependence. 
Measurements
Diagnostic instrument
Diagnoses of psychiatric disorders according to DSM­III­R (APA, 1987) were based on the 
Composite International Diagnostic Interview (CIDI), version 1.1 (computerized version) 
(Smeets & Dingemans, 1993). The CIDI is a structured interview developed by the World 
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Health Organization (WHO,1990) and has been found to have high inter­rater reliability 
and high test­retest reliability for most diagnoses (Wittchen, 1994). The following DSM­III­R 
diagnoses were recorded in NEMESIS: mood disorders (bipolar disorder, major depression, 
dysthymia), anxiety disorders (panic disorder, agoraphobia, simple phobia, social phobia, 
generalized anxiety disorder, obsessive­compulsive disorder), psychoactive substance use 
Table 1   Characteristics of 687 included subjects 
Number Percentage (%)
Socio­
demographic 
factors
Gender Female 467 68.0
Male 220 32.0
Age 18­24 28 4.1
25­34 187 27.2
35­44 236 34.4
45­54 162 23.6
55­64 74 10.8
Education Low 281 40.9
Medium 209 30.4
High 197 28.7
Cohabitation status Married or cohabiting 506 73.6
Employment Employed 483 70.3
Clinical 
factors
Severity index  
MDD episode
Mild 167 24.3
Moderate 216 31.4
Severe 217 31.6
Family history Family history in first 
 degree members present
317 46.1
Number of 
previous episodes 
Single 323 47.1
Recurrent 364 53.0
Comorbidity
(lifetime)
Prevalence of anxiety 
 disorder (any) present
275 40.0
Prevalence of alcohol 
 dependence present
52 7.6
Prevalence of alcohol 
abuse present
74 10.8
Somatic illness
(12 months)
331 48.2
Psychosocial 
factors
Trauma before 
age 16
Present 192 27.9
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disorders (alcohol or drug abuse and dependence, including sedatives, hypnotics and 
anxiolytics), eating disorders, schizophrenia and other non­affective psychotic disorders. 
Prevalence rates were calculated using the hierarchical rules of the DSM, thus excluding 
MDEs occurring in schizophrenic and other psychotic disorders or in bipolar disorders.
Time to recurrence
A mentioned previously, the time to recurrence was assessed retrospectively at baseline 
and prospectively between T0 and T2. Using the prevalence rates (1­month, 6­month, 
1­year and 2­year) at T1 or T2, a period could be defined in which the recurrence of an 
MDE occurred and the average time of this period was calculated. For example, if a 
respondent had a 6­month prevalence of MDD at T1 but no 1­month prevalence at T1 and 
reported the last MDE 36 months before T0, it was estimated that the time to recurrence 
was 45 months (36 months before T0 plus 9 months between T0 and T1). 
Potential predictors for time to recurrence 
Sociodemographic, clinical and psychosocial factors were assessed, along with personality 
characteristics.
Sociodemographic factors.  These included gender, age, cohabitation status (categorized 
into living alone or not), educational attainment (categorized into low, medium and high) 
and employment status (categorized into paid employment or not).
Clinical factors.  With the CIDI, information was obtained on age of onset, severity of the 
last MDE (categorized into mild, moderate, and severe, with or without psychotic features), 
number of MDEs (categorized into single or recurrent) history of MDD in first­degree 
family members (categorized into yes or no) and lifetime comorbidity with other mental 
disorders. The co­morbid disorders we deemed relevant were anxiety disorders, alcohol 
dependence and abuse. Co­morbidity with somatic illnesses was assessed with a 
questionnaire listing 31 mostly chronic somatic conditions. 
Psychosocial factors. Several psychosocial factors were measured at T1. Life events and 
ongoing difficulties were recorded with a semi­structured interview­based questionnaire 
(De Graaf et al. 2002; Spijker et al. 2004) based on information about life events and 
difficulties in the manual of the Life Events and Difficulties Schedule (LEDS) (Brown & 
Harris, 1987). The occurrence of the following nine negative life events in the 12 months 
preceding T1 were recorded: adverse change in health status, adverse change in health 
status of a significant other, adverse change in important domains (such as loss of 
employment, divorce), adverse change in important domains of a significant other, 
adverse change in living conditions, expected adverse changes in the future, failure to 
attain an important goal, another important self­reported distressing event (like physical 
threat or assault, sexual violence, discrimination), or another important distressing event of 
a significant other. The presence of three distressing ongoing conflicts or difficulties in the 
12 months preceding T1
 
were recorded: relationship problems, conflicts at work or school, 
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private or occupational problems (like noise exposure, financial difficulties). These are 
persisting situations which usually develop gradually and form a continuous source of 
daily problems and concerns. Because the impact of specific events can vary, depending 
on their context or their meaning for the individual, we questioned respondents on their 
subjective perception of the effects that each event had had on their own mental health.
Furthermore, the recency of life event and ongoing difficulties was assessed. Only ongoing 
difficulties or life events experienced as ‘a significant influence’ preceding recurrence were 
included. The outcome was categorized into ‘yes’ or ‘no’. The subjective experience of 
social support between T0 and T1 was measured by the Social Support Questionnaire for 
Satisfaction with the supportive transactions (SSQS) (Doeglas et al. 1996; Suurmeijer et al. 
1996) with 23 items. The internal reliability of the SSQS in the research cohort was high 
(Cronbach’s α = 0.88). Childhood experiences of emotional neglect, emotional or physical 
abuse or sexual abuse before age 16 were recorded. The answers for neglect and for 
emotional and physical abuse were categorized into ‘once to sometimes’ versus ‘regular 
to frequent’ and the answers for sexual abuse into ‘never’ versus ‘once or more’. Negative 
youth experiences were present if the respondent confirmed emotional or physical abuse 
on a regular to frequent basis or if the respondent had experienced sexual abuse once or 
more. 
Personality characteristics: Neuroticism was assessed with the Groningen Neuroticism 
Questionnaire containing 14 items (Ormel, 1980).The internal reliability of the questionnaire 
in our research cohort (Cronbach’s α = 0.75) was satisfactory. Locus of control was assessed 
with the 5­item Mastery Scale (Pearlin & Schooler, 1978), with high scores on mastery 
corresponding to an internal locus of control. The internal reliability of this questionnaire 
in our research cohort (Cronbach’s α = 0.78) was satisfactory. 
Statistical methods
We used Kaplan­Meier survival curves to estimate the time to recurrence of MDD during 
the follow­up period. The primary outcome variable was the recurrence of MDD (yes/no) 
during the 3­year follow­up period. Hazard ratios and their 95% confidence intervals (95% CI) 
were calculated using Cox regression analyses in SPSS for Windows Version 17.0 (SPSS Inc., 
USA).  Predictors that had a p­value ≤ 0.1 in the bivariate analyses were included in 
multivariate analyses. The stepwise backward method (Pin ≤ 0.05 and Pout ≥ 0.10) was 
used. In these analyses, censored data included subjects who had not met the criteria for 
the endpoint event of analysis, either by the end of the follow­up period or by the time 
they left the study. 
43
Recurrence of MDD in the general population
3
3.3.  Results
Time to recurrence
Because we could assess the timing of the last MDE retrospectively, it was possible to 
assess the occurrence of recurrence over a long period of time. A total of 135 respondents 
had a MDE during follow­up (Fig. 1). The median time to recurrence was 6 years (s.d.=5.5). 
The estimated cumulative recurrence percentage of MDD, after a duration of remission of 
at least 6 months, was 2.5% after 1 year, 4.5% after 2 years, 13.2% at 5 years, 23.2% at 10 
years and 42.0% at 20 years . 
Predictors
Table 2 shows the potential risk factors, corrected for age and gender, of time to recurrence 
of MDD using bivariate and multivariate Cox proportional regression analyses respectively. 
In bivariate analyses of the sociodemographic factors, age was found to be associated 
with recurrence of MDD, with each additional year of age lowering the risk for recurrence 
by 0.04 (95% CI 0.94­0.98, p<0.001). The younger age group (18­30 years) had a HR of 3.8 in 
comparison with the older age group (50­65 years). In addition, a younger age of onset 
Figure 1   Survival curve of time to recurrence of MDE in a cohort from NEMESIS,  
+ censored
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was also related to a faster recurrence. Because there was a correlation between age of 
onset and age (Pearson correlation 0.68, p<0.001), this variable was not analyzed in the 
multivariate Cox proportional hazards model. Among the clinical factors, a history of 
recurrent episodes and severity of the last depressive episode were significant predictors 
for a shorter time to recurrence. However, the percentage of missing data was high in the 
variable ‘severity of the last depressive episode’ (12.8%, N=88). We analyzed the missing 
data and found that this was more common in women (x2=5.16, df=1, p=0.02) and 
respondents who had (only) experienced a single episode of MDD (X2=5.01, df=1, p=0.03). 
High neuroticism also was associated with a shorter time to recurrence of MDD.  Of the 
psychosocial factors, negative youth experiences and ongoing difficulties were significant 
predictors. In multivariate Cox proportional hazards analyses (adjusted for gender), the 
missing data of the variable ‘severity of the last MDE’ were excluded. Younger age, a high 
number of previous episodes, a severe last depressive episode, negative youth experiences 
and the presence of ongoing difficulties before recurrence remained significant predictors 
of time to recurrence. 
 Furthermore, we assessed the cumulative recurrence percentage of MDD (posteriori 
hypotheses) of the respondents who had zero, one, two, three, or more than four of the 
predictors found in multivariate Cox proportional hazards analyses (Fig. 2). The number of 
respondents with five predictors was too small to analyze (n=5). The predictor ‘age’ was 
dichotomized into younger or older than 30 years. We found that the risk of recurrence 
depended on the number of predictors the respondents had; after 10 years the cumulative 
recurrence percentage of MDD was 3.4% for respondents with no predictors (N=78), 19.0% 
for respondents with one predictor (N=175), 26.6% for those with two predictors (N=197), 
56.5% for those with three predictors (N=97) and 65.0% for those with more than four 
predictors (N=49) (log rank, X2=63.77, df=4, p<0.001). 
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3.4.  Discussion 
This is one of the few studies, using a large general population cohort, on the incidence 
and predictors for recurrence of MDD among people who had recovered from their last 
episode of MDD. Several conclusions can be drawn. First, the cumulative incidence of 
recurrence after 20 years was found to be 42.0%. This percentage is higher than that which 
has been found in previous research (Eaton et al., 2008; Mattison et al., 2007) but it is 
difficult to compare these studies because of differences in duration of remission, 
follow­up, diagnosis and population. The study by Eaton et al. (2008) is the most similar to 
ours with a percentage of recurrence of 35% over 23 years. However, one of the major 
differences with this study was that their cohort contained exclusively first incidence 
cases; the inclusion criteria of remission was different, at least 1 year in their study 
compared with 6 months in ours. As a consequence, our cohort contained more 
respondents, with a shorter time to recurrence, as well as respondents with multiple 
recurrences. Mattison et al. (2007) observed a lifetime recurrence percentage of 40% but 
Figure 2   Survival curve of time to recurrence of MDE in a cohort from NEMESIS
Divided into respondents with 0 (N=78), 1 (N=175), 2 (N=197), 3 (N=97)  or more than 4 (N=49) 
predictors respectively (age  under 30 years, ongoing difficulties present, traumatic youth 
experiences present, severe last depressive episode, recurrent MDD). Number of predictors: 0 (+),  
1 ( ),  2 ( ), 3 ( ), 4 ( ).
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used a broader definition of depression, also including dysthymia. Our percentage for 
recurrence of MDD is, however, still lower than that which has been found in a specialized 
mental health care setting (85% in 15 years) (Mueller et al., 1999). Evidently, the discrepancy 
in recurrence risk of MDD between settings (general population versus specialized mental 
health care) is considerable. Second, the following variables predicted shorter time to 
recurrence in the bivariate models: younger age, younger age of onset, a large number of 
previous episodes, a more severe last depressive episode, negative youth experiences, the 
presence of ongoing difficulties before recurrence and high neuroticism. Multivariably, 
younger age, greater number of previous episodes, a severe last depressive episode, 
negative youth experiences and ongoing difficulties remained significant. Because 
previous large­scale general population­based follow­up studies have mainly focused on 
the risk of recurrence of MDD and not on the determinants of recurrence, it was not 
possible to fully compare our results with previous research. However, Eaton et al. (2008) 
also studied the main socio­demographic factors and found similar results; the 18 to 
29­year­old group had a higher risk for recurrence, a younger age of onset  was a significant 
predictor of time to recurrence (Eaton et al., 2008) and no other sociodemographic 
variables were related to a shorter time to recurrence. Third, our data suggests that the risk 
for recurrence of MDD depends on the number of predictors that are present. However, 
because this is a data­derived model, in other words we have included those risk factors 
which are modelled to be most strongly associated with recurrence, no firm conclusions 
can be drawn and these observations should be tested in future studies.
 Previous research in NEMESIS (De Graaf et al., 2002) found that female gender, 
negative life events, ongoing difficulties, and a high level of neuroticism in multivariate 
analysis were associated with first incidence of MDD. By contrast, our study did not find 
that female gender was related to recurrence. However, both studies found that 
stress­related factors seem to play a role, and additional clinical factors related to past 
MDD episodes (number of previous episodes, severity of the last episode) emerged.
 Our study has a number of strengths. It was performed in a large cohort from the 
general population, thereby avoiding selection bias. In addition, as all respondents were 
in remission from a MDE at baseline, the measurement of the predictors was not influenced 
by the presence of MDE, apart from the psychosocial predictors (life events, social support, 
ongoing difficulties) which were measured at follow up (T1). 
In interpreting the results of this study, its limitations should be noted. First, we assessed 
cases with a lifetime diagnosis of MDD, and assessed the last depressive episode in 
retrospect using the CIDI. As a consequence, the assessment of the age of onset and 
recency of the last depressive episode may not have been measured exactly, and therefore 
the risk of recurrence may have been selectively underestimated in subjects who 
experienced a MDD at an earlier point in time. This would lead to an overestimation of the 
time to recurrence and an underestimation of the number of recurrences a respondent 
had. In addition, the severity of MDD may not be measured accurately, especially among 
48
Chapter 3
respondents who had a MDE at an earlier point in time. Furthermore, the difference in 
time between the end of the last MDE and the measurement of predictors may have led 
to an overestimation of the effect of the predictor on recurrence.  Second, only respondents 
were included who had a duration of remission of at least 6 months, implying that 
respondents with a shorter time to recurrence were not included. As the literature on this 
subject is still scarce, we also analyzed the recurrence rate of MDD in respondents with a 
duration of remission of at least one month. 764 respondents were included in this 
analysis, of whom 155 had a MDE during follow­up. The number of respondents included 
was higher in this analysis because fewer respondents were excluded at baseline. As 
expected, the incidence of recurrence was slightly higher: 3.9% after 1 year, 5.9% after 2 
years, 15.1 % after 5 years, 25% after 10 years, and 43.3% after 20 years. Third, despite the 
inclusion of a large number of predictors, subclinical residual symptoms, which is an 
important predictor of recurrence of MDD (Hardeveld et al. 2010), could not be assessed. 
It was also not possible to study dysthymia (as an equivalent) because the number of 
respondents with a 6­month prevalence of dysthymia at T0 was small (N=17) and we 
could not assess whether the dysthymia had occurred before or after the MDD. Fourth, 
the resulting HRs were an average of the whole period but it is likely that the hazard 
changes over time, being greater in the beginning. Previous literature (Mueller et al., 1999) 
has also suggested that the risk of recurrence is greater earlier on. If the risk of recurrence 
declines over time, the effect of the factors determining this risk may also not be constant. 
Moreover, the Cox regression model is built on the assumption that predictors remain 
constant during follow up, which may not be true for some predictors. Furthermore, 
although the study is in part a prospective cohort, it is less capable of confirming causality 
between a predictor and recurrence of MDD. Therefore, the possibility remains that the 
previous depressive episode has affected the presence and the effect of potential 
predictors, or even that some of these risk factors are a consequence of previous episodes. 
The question remains, for example, as to whether ongoing difficulties contribute to 
recurrence of MDD, or multiple recurrences generate ongoing difficulties. Finally, our 
cohort contained respondents with varying numbers of previous episodes. It could be 
that the predictors of recurrence change over subsequent episodes. For example, previous 
research (Kendler et al., 2000) suggested that life events were a significant risk factor during 
the first episodes, but when the numbers of episodes increased, life events were no longer 
a relevant predictor.  
 What directions does this study provide for future research? Various possible genetic 
and other biological predictors were not studied, but it seems likely that both genetic and 
environmental factors are involved and interact with one another (Caspi et al., 2003). 
Future research should focus on this interaction. Furthermore, ongoing difficulties 
preceding recurrence of an MDE seems to be an important predictor. The link between 
ongoing difficulties, which could cause (chronic) stress, and negative youth experiences 
which were also a predictor of recurrence is of particular interest. Previous research (Heim 
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et al., 2002) concluded that the HPA­axis could be dysregulated following traumatic 
childhood exposure. Subjects who have a dysregulated HPA­axis and experience ongoing 
difficulties might be at a higher risk for recurrence. Our data supports this association, but 
long­term prospective studies should further elucidate this finding. 
 What are the implications of our findings? Long­term naturalistic studies performed 
in mental health care have underscored the importance of understanding depression as 
a lifelong and recurrent illness, with a number of possible courses. It also seems that in the 
general population, subjects who have experienced a MDE have a long­term vulnerability 
for recurrence which could be triggered under certain circumstances. Subjects were 
found to have a higher risk for an earlier recurrence of MDE if they are younger, had 
negative youth experiences, had multiple previous episodes, experience ongoing 
difficulties, and had a more severe last episode. Clinicians should be aware of these risk 
factors and consider long­term treatment with antidepressants (Geddes et al. 2003; 
Kaymaz et al. 2008) or additional psychological treatment, for example preventive 
cognitive therapy (Bockting et al. 2009). Preventive programmes for recurrence of MDD 
also appear to be cost­effective (Scott et al. 2003). Moreover, not only is it important to 
know who will have a fast recurrence but also which group of patients will experience 
multiple recurrences in their lives. With this knowledge we might be better able to classify 
and stage the different course patterns of this disabling disorder and chose the appropriate 
treatment.  

Recurrence of major depressive disorder 
across different treatment settings:  
results from the NESDA study
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Abstract
Objective: Examine time to recurrence of major depressive disorder (MDD) across 
different treatment settings and assess predictors of time to recurrence of MDD. 
Methods:  Data were from 375 subjects with a MDD diagnosis from the Netherlands 
Study of Depression and Anxiety (NESDA). The study sample was restricted to subjects 
with a remission of at least three months. These subjects were followed until recurrence 
or the end of the two year follow­up. DSM­IV based diagnostic interviews and Life Chart 
Interviews were used to assess time to recurrence of MDD across treatment settings. 
Predictors of time to recurrence were determined using Cox’s proportional hazards 
analyses. 
Results: Although trends indicated a slightly higher rate of and shorter time to recurrence 
in specialized mental health care, no significant difference in recurrence rate (26.8% versus 
33.5%, p=0.23) or in time to recurrence (controlled for covariates) of MDD was found 
between respondents in specialized mental health care and respondents treated in 
primary care (average 6.6 versus 5.5 months, p=0.09). In multivariable analyses, a family 
history of MDD and previous major depressive episodes were associated with a shorter 
time to recurrence. Predictors did not differ across treatment settings. 
Limitations: The study sample may not be representative of the entire population treated 
for MDD in specialized mental health care.
Conclusions: Health care professionals in both settings should be aware of the same risk 
factors since the recurrence risk and its predictors appeared to be similar across settings. 
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4.1.  Introduction
Major depressive disorder (MDD) is among the leading causes of disability worldwide. This 
is largely due to its highly chronic and recurrent nature (Murray et al., 1997; Vos et al., 2004). 
The risk of recurrence after a first major depressive episode is 50% and increases with 
subsequent episodes (Post, 1992; Kupfer et al., 1996; American Psychiatric Association, 
2000). Efforts to reduce the disabling effects of depression should be expanded with 
recurrence prevention strategies, especially in patients at high risk of recurrence (Bockting 
et al., 2011). Strategies to prevent recurrence of a major depressive episode can be highly 
effective. A meta­analysis found a number needed to treat (NNT) of five (Hansen et al., 
2008). In comparison, the number needed to treat to prevent one major cerebrovascular 
event with aspirin over a mean follow­up of 6.9 years is 253 (Berger et al., 2011). However, 
knowledge of recurrence risk of MDD is incomplete (Hardeveld et al., 2010). It is still difficult 
to identify high risk groups, and data on MDD recurrence risk is mainly based on studies 
performed in specialized mental health care. It is important to understand the extent to 
which this information can be generalized to patients in primary care settings, where the 
majority of people with MDD are treated. If the risk of recurrence in MDD patients treated 
in primary care differs from those in specialized mental health care, different recommen­
dations for prevention of recurrence are needed. This knowledge might facilitate further 
improvements in the quality and cost­effectiveness of depression management.
 We expect the risk of recurrence of MDD to be higher in specialized mental health 
care than that in primary care since those with the most severe, complex, recurrent and 
long­lasting disorders are more often treated in specialized mental health care (Cooper­
Patrick et al., 1994; Suh and Gallo, 1997). However, this hypothesis is not well documented, 
mainly because data on the risk of recurrence among MDD patients in primary care 
settings are scarce (Gilchrist et al., 2007; Hardeveld et al., 2010) and, in particular, prospective 
longitudinal studies are lacking. 
 Furthermore, it is important to be aware of the predictors of recurrence of MDD. This 
knowledge would make it possible to identify patients with a high risk for recurrence. 
Predictors of recurrence of MDD might be different across treatment settings. The studies 
available to date, which have aimed to identify risk factors for recurrence, have largely 
been carried out in specialized mental health care. The results suggest that subclinical 
residual symptoms and the number of previous episodes are the most important 
predictors for recurrence of MDD, whereas demographic factors are not related to 
recurrence of MDD (Hardeveld et al., 2010). To our knowledge, a study on risk factors for 
(time to) recurrence among patients treated in the specialized mental health care as well 
as those in primary care – also allowing a direct comparison ­ has not been done.
 The aim of this study was therefore to examine the time to recurrence of MDD and its 
predictors among subjects who recovered from their last episode of MDD, and compare 
the findings between primary care and specialized mental health care. 
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4.2.  Methods
Study sample
Data were from the Netherlands Study of Depression and Anxiety (NESDA), an ongoing 
longitudinal cohort study, which began in 2004, and examines the long­term course of 
depressive and anxiety disorders in different health care settings. The study protocol was 
approved centrally by the Ethical Review Board of the VU University Medical Centre, and 
subsequently by local review boards of each participating centre. All respondents 
provided informed consent. For the present study, data from the first two years of 
follow­up were used. The rationale, objectives, and methods of NESDA have been 
described in detail elsewhere (Penninx et al., 2008). In brief, the NESDA cohort (N=2981) 
consists of respondents (18­65 years) with (i) a current anxiety and/or depressive disorder, 
(ii) a prior history of a depressive and/or anxiety disorder and (iii) healthy controls. All 
respondents were administered a baseline assessment, which included evaluation of 
 psychopathology, demographic and personal characteristics, psychosocial functioning, 
and biomarkers. Respondents were recruited in primary care through a screening 
procedure, in specialized mental health care when newly enrolled, and in the community. 
Respondents with a primary diagnosis of a psychotic disorder, obsessive­compulsive 
disorder, bipolar disorder, a severe addiction disorder, or who were not fluent in Dutch 
were excluded.
 For our study sample, the classification of treatment settings (primary care versus 
specialized mental health care) was based on the recruitment setting but this was also 
confirmed with data from the Trimbos/iMTA questionnaire for Costs associated with 
Psychiatric Illness (TIC­P) (Hakkaart­van Roijen, 2002). The TIC­P is a fully structured interview 
that assesses loss of productivity, health care utilization, and costs. Respondents were 
asked whether they had sought help for mental problems within the past six months. 
Those who had not sought help were not included because we wanted to compare 
respondents treated in specialized mental health care with those treated in primary care. 
Respondents were considered to be under treatment in specialized mental health care or 
primary care if they had at least two contacts in the six months prior to the baseline 
interview. The sources of care included primary care (general practitioner, first line 
psychologist, social worker, social psychiatric nurse) and specialized mental health care 
(ambulatory mental health care including a psychiatrist/psychotherapist working in 
private practice and residential mental health care).
 Diagnoses of MDD were based on the Composite International Diagnostic Interview 
(CIDI), Lifetime Version 2.1 (WHO Lifetime Version 2.1). The CIDI is a structured interview 
developed by the World Health Organization and has been found to have high inter­rater 
reliability (Wittchen et al., 1994), high test­retest reliability (Wacker et al., 2006), and 
satisfactory validity for depressive and anxiety disorders (Wittchen et al., 1989; Wittchen, 
1994).
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 The study sample was restricted to subjects with a MDD diagnosis in the six months 
prior to baseline assessment, who were symptomatic in the month prior to baseline, and 
achieved remission during the two­year follow­up. In this way we tried to select a large 
sample of respondents who also had a MDD at baseline. Accordingly, the sample was 
limited to 706 subjects with a MDD diagnosis who confirmed symptoms in the month 
prior to baseline either through the CIDI recency questions or the Life Chart Interview (LCI) 
(Lyketsos, 1994) and who sought help for their MDD. Of these subjects, 566 (80.2%) 
participated in the two­year follow­up, of which a further six respondents were excluded 
because they did not have a (complete) LCI during follow­up. Drop­out was associated 
with lower educational attainment (p=.01), but not with gender, age, severity of the last 
major depressive episode (MDE) or number of previous episodes of MDD. A further 142 
respondents were excluded because they did not achieve remission from MDD within the 
two­year follow­up. Remission was defined as a reduction of symptoms to no or minimal 
severity for at least three consecutive months using the LCI. This three­month criterion is 
in line previous research (Spijker et al., 2002). During follow­up the percentage of 
respondents achieving remission was not statistically significant (19.0% in primary care 
versus 24.0% in specialized mental health care, chi­square=1.33, df=1, p=0.25). Finally, 43 
respondents were excluded because the diagnosis was changed to bipolar disorder during 
follow­up. So, the sample ‘at risk’ for a recurrence of MDD consisted of 375 respondents. Of 
those recruited from the community,  21 respondents were treated in specialized mental 
health care and twelve in primary care after checking data from the TIC­P. Furthermore, 29 
respondents which were recruited in primary care were treated in specialized mental 
health care. As a consequence, 97 were treated in primary care (25.9%) and 278 (74.1%) 
were treated in specialized mental health care. A flow­chart is displayed in Fig. 1. 
Time to recurrence
Time to recurrence was assessed prospectively during the two­year follow­up using the 
LCI. For each month with reported symptoms, severity was assessed (no or minimal 
severity, mild, moderate, severe, or very severe). Recurrence was operationalized as a 
return of symptoms after remission to at least mild severity level persisting for at least one 
month with the additional criterion that a CIDI­confirmed MDD diagnosis was present 
during follow­up. 
Determinants of time to recurrence
The following variables that we considered relevant as determinant of time to recurrence 
or as covariate and were assessed at baseline with several semi­structured questionnaires:
Socio-demographic factors. Gender, age, and level of educational attainment (in years of 
education).
Clinical factors:  Using the CIDI, the following information was obtained: age of onset of 
MDD, severity of the MDE in the month preceding baseline assessment (based on number 
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of DSM­criteria and categorized into mild, moderate and severe), and lifetime number of 
MDEs categorized into single or recurrent. Information on the duration of symptoms prior 
to baseline was derived from the baseline LCI that assessed the percentage of time the 
respondent spent with depressive symptoms in the previous year. History of depression in 
first­degree family members was assessed using a family tree inventory (Fyer & Weissman, 
1999), categorized into yes or no. The comorbid disorders that we deemed relevant 
were lifetime alcohol abuse/dependence or any anxiety disorder (panic disorder, social 
phobia, generalized anxiety disorder, agoraphobia) within the six months before baseline. 
Comorbidity with somatic illnesses was assessed by means of a questionnaire listing 
twenty mostly chronic disorders for which the respondent was treated. 
Psychosocial factors: Neuroticism was measured with the twelve­item subscale of the 
NEO Five­Factor Inventory (NEO­FFI) Questionnaire ranging from 0 (low neuroticism) to 48 
(high neuroticism) (Costa & McGrae, 1995). Negative life events in the last year were 
determined with the Brugha questionnaire ranging from 0 to 5 (Brugha et al., 1985) and 
included 12 specific events and one ‘other’ category asking about other serious negative 
life events. In order to examine the role of childhood trauma, a cumulative childhood 
index using the NEMESIS childhood trauma interview was constructed (De Graaf et al., 
2004; Wiersma, 2009; Hovens et al., 2010). Participants were asked four questions regarding 
childhood experiences of emotional neglect, or emotional, physical, or sexual abuse. The 
cumulative index was calculated for each participant as the sum of the number and 
frequency of the four types of abuse (range, 0­8).
Treatment: Respondents were asked about the type of treatment they had received for 
their MDD, subdivided into pharmacological treatment and psychological treatment. 
Pharmacological treatment was assessed based on inspection of the medication boxes 
Figure 1   Flow chart of selection process for study population
Baseline population (n=2981) 
Study population at baseline (n=706)
Excluded:
• No MDD at baseline (n=2137)
• No treatment (n=138)
Study cohort (n=375) 
Excluded:
• drop-out (n=140)
• no life chart interview coverage (n=6)
• no remission of MDD (n=142)
• diagnosis changed to bipolar disorder (n=43)
 
 
Primary care
(n=97)
 
 
Specialized mental
health care (n=278)  
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used in the past month and coded using the WHO Anatomical Therapeutic Chemical 
(ATC) classification (REF to URL). Use of antidepressants was taken into account when the 
medication was taken at least 50% of the time and included selective serotonin reuptake 
inhibitors (ATC­code N06AB), tricyclic antidepressants (N06AA) or other antidepressants 
(N06AF/N06AX). The receipt of psychological treatment (psychotherapy, counselling, and 
skills training) was based on self­report.
Statistical methods
For the analyses, SPSS for Windows Version 17.0 (SPSS Inc., USA) was used. Descriptives 
across treatment setting (primary care, specialized mental health care) were compared 
using independent t­tests for continuous variables and chi­square tests for categorical 
variables. A two­tailed p ≤ .05 was considered statistically significant. We used Kaplan­Meier 
survival curves to estimate the time to recurrence of MDD during follow­up across 
treatment settings. Subjects who ­ at the end of the follow­up period ­ did not meet the 
criteria for the endpoint event (recurrence) were censored. Subsequently, we studied 
possible predictors of recurrence of MDD (including treatment setting) using Cox’s 
proportional hazards analyses. Predictors that had a p­value ≤ .20 in the univariable 
analyses were included in multivariable analyses in which the forced entry method was 
used. Time to recurrence of MDD (yes/no) during the two­year follow­up was the main 
outcome measure. Because the number of subjects treated in primary care was relatively 
small (n=97) we could not make a separate comparison of the predictors of recurrence 
between settings. Instead, we added a setting by predictor interaction term to check whether 
possible differences in recurrence risk between treatment settings were explained by 
differences in predictors. 
4.3.  Results
Characteristics
The mean age of the study sample was 40.3 years, and 66.9% were female. The socio­ 
demographic, clinical and treatment variables are shown by setting in Table 1. 
 Respondents treated in specialized mental health care were younger, had a younger 
age of onset, had a higher neuroticism score and a higher percentage had psychological 
treatment and/or medication (p<.05). Table 2 describes the course characteristics of MDD 
during follow­up. Percentage of recurrence, mean and average time to recurrence and 
average duration of follow­up did not differ significantly between treatment settings.  
Recurrence risk
During the two­year follow­up, 26.8% (n=26) of respondents in primary care and 33.5% 
(n=93) treated in specialized mental health care experienced a recurrence of MDD after 
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having achieved remission for at least three months (chi­square=1.47, df=1, p=0.23) (see 
inclusion criteria). Fig. 2 shows the survival curve of MDD recurrence across different 
settings. The slope of the survival curve suggests that the risk of recurrence is highest in 
the first months after recovery, regardless of treatment setting. There was no significant 
Table 1   Characteristics of 375 subjects at risk for a recurrence of MDD from the  
NESDA study by treatment setting 
Primary care (n=97) Specialized 
mental 
health care 
(n=278)
p*
Socio-demographic factors
Gender  (% female) 70.1 65.8 0.44
Age (mean yrs, sd) 43.9 (12.1) 39.1  (11.7) <0.01
Educational attainment ( mean yrs, sd) 11.5 (3.1) 11.4 (3.0) 0.75
Clinical factors
Age of onset (mean yrs, sd) 30.4 (14.0) 27.1 (12.5) 0.03
Family history of depression (%) 87.6 85.6 0.62
Severity of the last MDE (CIDI) Mild 38.1 27.3 0.13
Moderate 28.9 31.7
Severe 33.0 41.0
Recurrent MDD (%) 53.8 51.1 0.66
Percentage months with symptoms  
of MDD in past year (mean, sd)
0.6 (0.4) 0.7 (0.3) 0.08
Anxiety disorder (any, 6 months) 59.8 68.0 0.14
Alcohol abuse/dependence (lifetime) 37.1 29.5 0.16
Number chronic somatic illness (mean 
number, sd)
0.8 (1.2) 0.6 (0.9) 0.12
Psychosocial factors
Trauma before age 16 (mean score, sd) 1.0 (1.2) 1.3  (1.2) 0.07
Negative life events (mean, sd) 1.2 (1.36) 0.9 (1.09) 0.06
Neuroticism (mean score, sd) 29.0 (6.6) 31.1 (6.5) <0.01
Treatment
Pharmacological treatment (% yes) 49.5 65.1 <0.01
Psychological  treatment (% yes) 45.4 63.3 <0.01
*  P­value based on chi­square statistics for categorical variables and independent t­test for continuous 
variables in bold: statistically significant
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Table 2   Course characteristics of 375 respondents at risk for a recurrence of MDD  
from NESDA by setting 
Primary 
care 
Specialized  
mental health care
p*
Percentage of recurrence (%) 26.8 33.5 0.23
Average time to recurrence (months) 6.6 5.6 0.30
Median time to recurrence (months) 5.5 5.0 0.30
Average duration of follow­up (months) 15.3 14.1 0.21
* Pearson Chi­square and Mann­Whitney U test used, uncontrolled for covariates
Figure 2   Survival curve of time to recurrence of MDE across different settings in a  
cohort from NESDA 
Log­rank (Mantel­Cox): X2=1.66, df=1, p=0.20
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Table 3   Univariable and multivariable analyses of potential predictors of time to 
recurrence of MDE in a cohort from NESDA (n=375) 
Time to recurrence
Univariable analyses Multivariable analyses*
HR 95% CI p HR 95% CI p
Socio-demographic factors
Gender, female 1.43 0.95­2.16 0.09 1.42 0.92­2.20 0.11
Age (yrs) 0.99 0.97­1.00 0.13 0.99 0.97­1.01 0.33
Educational attainment (yrs) 1.03 0.97­1.10 0.29
Clinical factors
Age of onset (yrs) 0.99 0.98­1.0 0.11 1.00 0.98­1.02 0.80
Family history of depression Yes 2.16 1.09-4.26 0.03 2.12 1.07-4.22 0.03
Severity of the last MDE Mild 1 ­ ­
Moderate 0.95 0.60­1.52 0.84
Severe 1.11 0.72­1.72 0.63
Recurrent MDD  
(% recurrent) 
1.61 1.10-2.35 0.01 1.59 1.08-2.35 0.02
Percentage months  
with symptoms of MDD  
in past year 
0.87 0.53­1.50 0.60
Anxiety disorder (any) Yes 0.90 0.62­1.31 0.60
Alcohol abuse/dependence  Yes 0.88 0.59­1.30 0.51
Number chronic somatic 
illnesses
High 1.05 0.88­1.24 0.61
Psychosocial
Trauma before age 16 High 1.10 0.95­1.26 0.22
Life events Low 1.02 0.87­1.19 0.81
Neuroticism High 1.00  0.97­1.03 0.93
Treatment
Pharmacological treatment No 1.29  0.90­1.86 0.16 1.16 0.80­1.68 0.43
Psychological  treatment No 1.64  0.81­1.67 0.41
Setting
Specialized mental  
health care
1.32 0.86­2.05 0.21
* forced entry method used if in univariable analyses p≤.20.  
in bold: statistically significant
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difference in time to recurrence of MDD between respondents in specialized mental 
health care in comparison with respondents treated in primary care (HR 1.32, CI 0.86­2.05, 
p=0.21). When controlled for socio­demographic, clinical, psychosocial and treatment 
factors, time to recurrence did not differ significantly, but a trend was found towards a 
shorter time to recurrence in specialized mental health care (HR=1.52, 95% CI=0.93­2.48, 
p=0.09). 
Table 3 shows the potential risk factors of time to recurrence of MDD using both univariable 
and multivariable Cox proportional regression analyses. Analyses showed that the 
presence of a family history of depression and having a previous MDE were associated 
with a shorter time to recurrence of MDD. In multivariable analyses, the presence of a 
family history of depression (HR= 2.12, 95%CI=1.07­4.22, p=0.03) and having a previous 
MDE (HR=1.59, 95% CI=1.08­2.35, p=0.02) remained significant predictors of time to 
recurrence. Finally, no significant interaction terms were found for treatment setting by 
predictor, implying that predictors of time to recurrence did not differ across treatment 
settings.  
4.4.  Discussion
To our knowledge, this is the first prospective naturalistic cohort study to directly compare 
the recurrence risk and predictors of time to recurrence in subjects with a MDD diagnosis 
across different treatment settings. The results indicate that the time to recurrence during 
the two­year follow­up did not differ between patients treated in primary care and in 
specialized mental health care. Given the presence of more severe, more treatment 
resistant, chronic and more complex patients in specialized mental health care, one might 
expect that the risk of recurrence would be higher in this care setting. However, our 
findings are in line with previous studies carried out in primary care (Lin et al., 1998; 
Gopinath et al., 2007; Vuorilehto et al., 2009; Suija et al., 2011). In a study performed in 
primary care among 386 respondents (Gopinath et al., 2007), 31.1% of patients had a 
recurrence after one year. Similar results were found in a study by Lin et al. (1998) (37.1% 
after one year), Vuorilehto et al. (2009) (27% after 15 months) and Suija et al. (2011) who 
observed a recurrence percentage of 28% after one year. In comparison, in specialized 
mental health care the percentage of MDD recurrence after one year ranges from 21% to 
37% (Kanai et al., 2003; Maj et al., 1992; Hardeveld et al., 2010). Although remaining non­sig­
nificant, a trend towards a shorter time to recurrence in specialized mental health care was 
noticeable (HR=1.52, 95% CI=0.93­2.48, p=.09) and the hazard ratio increased from 1.32 to 
1.52 when corrected for all covariates, suggesting that the risk of recurrence increases in 
secondary care in comparison with primary care and was confounded by these variables. 
A possible explanation for the similar recurrence risk found across treatment settings is 
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that the distribution of risk factors for MDD recurrence does not differ much between 
treatment settings. Previous research, also performed with NESDA data (Piek et al., 2011), 
found that patients were more likely to be referred to secondary care if they were younger, 
reported suicidal symptoms, had chronic depression, or were referred for psychotherapy. 
It seems that factors related to referral to specialized mental health care, in general, differ 
from predictors of recurrence. It could be that the decision to refer to specialized mental 
health care is determined to a greater exent by the need for acute treatment of MDD or 
the preferences of the patient than by expectations of a protracted course. When we 
excluded those who did not recover from a MDE during follow­up, respondents who 
were younger, had an earlier age of onset and a higher neuroticism score were most likely 
to be referred and treated in specialized mental health care. Although these could be risk 
factors for recurrence, our study found that the risk factors predicting a shorter time to 
recurrence were a history of recurrent MDEs and the presence of a family history of 
depression. These factors did not differ across treatment settings. An alternative explanation 
may be that those referred to specialized care receive more intensive treatment for 
recurrence prevention and that this reduced recurrence rate to a similar level as was found 
in primary care.
 As mentioned earlier, our study found that a history of recurrent MDD and the 
presence of a family history of depression predicted a shorter time to recurrence. Previous 
research also found these predictors to be related to recurrence of MDD (Maj et al., 1992; 
Mueller et al., 1999; Solomon et al., 2000). Family history of MDD, which had the highest 
hazard ratio for recurrence, is of special interest, because this might indicate an important 
genetic vulnerability for (the recurrence of) MDD. Further studies should examine this 
genetic basis, preferably prospectively, and should focus on predictors of recurrence early in 
the lifetime course. These studies should also take into account the interactions between 
genetic, biological, environmental, and clinical factors in concert, since causation of recurrence 
seems to be multifactorial with multiple putative causal factors that interact over time. 
 The strengths of our study are that we were able to examine a comprehensive set of 
predictors in a large representative sample and used standardized instruments to 
determine diagnosis and course. However, in interpreting the results of this study, one 
should also be aware of its limitations. First, the respondents treated in specialized mental 
health care were recently referred and, as a consequence, this sample is not representative 
of the entire population treated for MDD in specialized mental health care, since patients 
with more severe, chronic or frequent recurring MDD are probably underrepresented in 
the study. Consequently, the difference in recurrence risk between primary care and 
specialized mental health care could have been underestimated. On the other hand, the 
percentage of remission between respondents treated in primary care versus specialized 
mental health care was not statistically different in our study which suggests that the 
researched treatment cohorts are comparable in this way. Secondly, subclinical residual 
symptoms, which are a strong predictor of recurrence risk (Judd et al., 1998), could not be 
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included in the analysis because the data did not allow for such precision. It is reasonable 
to assume that residual symptoms are more common in respondents treated in specialized 
mental health care than in respondents treated in primary care. Thirdly, the follow­up 
duration of two years was relatively short if one takes into account that respondents had 
to have been in remission first. Although the average duration of follow­up was modest at 
approximately fifteen months, it is important to realise that the risk of relapse is greatest in 
the first year after recovery, and declines rapidly thereafter. Therefore, it is unlikely that the 
conclusions of the current paper would change if a longer follow­up period had been 
available. Finally, our results may have been influenced by the referral behaviour of general 
practitioners and may not be generalizable to health systems that are very different from 
the system in the Netherlands. However, the structure of the Dutch health care system is 
comparable to that of several other European countries in which the general practitioner 
serves as the gatekeeper and referrals are needed for access to specialized mental health 
care, and also the proportion of diagnosed persons receiving mental health treatment, as 
well as the quality of care received, is comparable to that in other high income countries 
(US, UK, Spain, Belgium) (Alonso et al., 2004; Wang et al., 2007). 
4.5.  Conclusion
In conclusion, the recurrence risk of MDD appeared to be similar in specialized mental 
health care and primary care meaning that the risk of recurrence in primary care is also 
considerable. Respondents with a history of recurrent MDD and a family history of MDD in 
first­degree relatives had a shorter time to recurrence. Patients with these risk factors 
should be closely monitored and treatment strategies to prevent recurrence should be 
considered. Our results also imply that prevention of recurrence of MDD is advised for 
high­risk groups, not only in specialized mental health care, but also in primary care. 
However, aside from pharmacological treatment (Kaymaz et al., 2008), other programmes 
to prevent recurrence, e.g. mindfulness­based cognitive therapy (Piet et al., 2011) and 
cognitive therapy (Beshai et al., 2011) are mainly carried out in specialized mental health 
care. Therefore, general practitioners should refer patients, not only for specialized 
treatment of depression, but also for prevention of recurrence. Another possibility is to 
expand these programmes beyond specialized mental health care. To improve the 
management of recurrence prevention of MDD, collaborative care models (Katon et al., 
2011), in which long term management and communication between primary­ and 
specialized mental health care professionals are optimized across psychiatric services, may 
be helpful. 
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Abstract
Introduction: Although HPA­axis activity has been studied extensively in relation to 
depression, there is no consensus whether HPA­axis parameters predicts major depressive 
disorder (MDD) recurrence. We investigated whether HPA­axis parameters (cortisol awakening 
response (CAR), the dexamethasone suppression test (DST) and evening cortisol) predict 
time to recurrence in remitted subjects with a history of MDD and whether childhood 
trauma and life events interact with HPA­axis parameters in increasing the risk for recurrence. 
Method: Data were derived from 549 subjects with a lifetime diagnosis of MDD in 
remission for at least six months preceding the baseline assessment of the Netherlands 
Study of Depression and Anxiety (NESDA). Subjects were followed up with two interviews 
over the course of four years to assess recurrence. DSM­IV based diagnostic interviews 
were used to assess time to recurrence of MDD. Seven salivary cortisol samples were 
collected at baseline with information on CAR, evening cortisol and the DST. Hazard ratios 
were calculated using Cox regression analysis, adjusted for covariates. 
Results: A higher CAR was associated with time to recurrence of MDD (HR=1.03, 95%CI 
1.003­1.060, p=0.03) whereas evening cortisol and DST were not. No interactions between 
HPA­axis parameters and stress­related factors were found. 
Conclusions: Our data support previous studies reporting that subjects with a higher 
CAR are more vulnerable to recurrence of MDD. 
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5.1.  Introduction
Major depressive disorder (MDD) is often a chronic or recurrent disorder (Judd, 1997) and 
is one of the most disabling disorders worldwide (World Health Organization, 2008). 
Prevention of recurrence is therefore an important goal in the management of major 
depression. To that end, further knowledge on pathogenic mechanisms underlying 
recurrence of major depression is needed. The hypothalamic pituitary adrenal (HPA) axis 
is one of the main neuroendocrine systems activated under stress. Hyperactivity of the 
HPA­axis among depressed patients is a rather consistent research finding (Stetler & Miller, 
2011) and alterations of the HPA­axis generally normalizes after full remission of depressive 
symptoms (Holsboer et al. 2000; Kaestner et al., 2005; Aihara et al., 2007; Pariante et al., 
2009; McKay & Zakzanis, 2010 et al., 2010). However, inconsistent findings have been 
observed (Bhagwagar et al., 2003; Mannie et al., 2007; Vreeburg et al., 2009(b); Lok et al., 
2012). Hyperactivity of the HPA­axis often results in hypercortisolism, which is associated 
with the pathophysiological pathway leading to MDD known as the glucocorticoid 
cascade hypothesis (Holsboer, 2000). A number of alterations in the HPA­axis found in 
major depression indicate hyperactivity of the HPA­axis. These are (i) hypercortisolism, 
resulting in a high evening cortisol (Kirschbaum & Hellhammer, 1989), (ii) an impaired 
circadian rhythm in terms of cortisol secretion in the first hour after awakening as reflected 
by an elevated cortisol awakening response (CAR) (Pruessner et al., 1997; Clow et al., 2010), 
(iii) a reduced negative feedback response to a dexamethasone suppression test (DST) 
(Ribeiro et al., 1993) and (iv) increased release of adrenocorticotrophic hormone (ACTH) 
and cortisol in response to corticotrophin­releasing hormone (CRH) after administration 
of 1.5 mg of dexamethasone, known as the combined dexamethasone/corticotrophin 
releasing hormone test (DEX/CRH test) (Nemeroff, 1996; Holsboer, 2000). 
 Although HPA­axis activity has been studied extensively in relation to depression 
(Stetler & Miller, 2011), there is no consensus on whether HPA­axis parameters have predictive 
value for recurrence of MDD. HPA­axis alterations may represent an underlying active disease 
process in depression and may predict risk for recurrence. Although a number of studies 
have examined this issue (Ribeiro et al., 1993; Zobel et al., 1999; Harris et al., 2000; Zobel et al., 
2001; Hatzinger et al., 2002; Appelhof et al., 2006; Aubry et al., 2007; Bhagwagar & Cohen, 
2008; Pintor et al., 2009; Rao et al., 2010; Bockting et al., 2012; Vrshek­Schallhorn et al., 2013), 
different HPA­axis measurements were used. Of the above mentioned studies, one study 
found that higher evening cortisol levels predicted recurrence (Rao et al., 2010), a literature 
review suggested that non suppression on the DST was related to relapse/recurrence 
(Ribiero et al., 1993), and five studies found an association between non­response on the 
DEX/CRH test and recurrence (Zobel et al., 1999; Zobel et al., 2001; Hatzinger et al., 2002; 
Appelhof et al., 2006; Pintor et al., 2009). However, also inconsistent findings have been 
reported,  e.g. a higher CAR predicted MDD recurrence in two studies (Harris et al., 2000; Vrshek 
et al., 2013) whereas a lower CAR was found to do so in another study (Bockting et al., 2012). 
68
Chapter 5
 It has also been suggested that early­life stress can induce persistent changes in the 
response of the HPA axis, which becomes especially visible when persons are exposed to 
psychosocial stressors in adulthood (Baes et al., 2012). A possible mechanism is reduction 
of glucocorticoid receptor function leading to a decrease in inhibitory feedback resulting 
in hypercortisolism. Rao et al. (2010) observed that the risk for recurrence was higher 
among those with elevated cortisol levels and recent life events. Therefore, when 
investigating the predictive value of HPA­axis parameters on recurrence of MDD, it is 
important to take a potential interaction effect of recent stressors and childhood trauma 
into account (Adam et al 2010). However, the literature is inconsistent, e.g. two other 
studies did not find any interactions (Bockting et al., 2012; Vrshek­Schallborn et al., 2013). 
 Since results are inconsistent and different HPA­axis parameters were measured, which 
makes previous studies difficult to compare, there is a need for further research. To our 
knowledge, large­scale prospective studies that examine different HPA­axis parameters 
simultaneously along with the interaction of HPA axis parameters with childhood trauma 
and life events are scarce and some of these studies only targeted adolescents (Rao et al., 
2010, Vrshek­Schallborn et al., 2013). We assessed whether HPA axis parameters predict 
recurrence in remitted adult MDD subjects and whether stress­related factors (childhood 
trauma, life events) interact with HPA­axis parameters in predicting recurrence. Since 
hyperactivity as well as hypo­activity have been found to be associated with recurrence 
of MDD, we will examine potential non­linear associations with recurrence. 
5.2.  Methods
Study sample 
Data were drawn from the Netherlands Study of Depression and Anxiety (NESDA), an 
ongoing longitudinal cohort study on the long­term course of depressive and anxiety 
disorders in different health care settings and illness phases. For the present study, we 
used the baseline assessment and follow­up assessments at two and four years. The study 
protocol was approved by the Ethical Review Board of the VU University Medical Centre 
Amsterdam and subsequently by the local review boards of each participating institute. 
All subjects provided informed consent. The rationale, objectives, and methods of the 
NESDA have been described in detail elsewhere (Penninx et al., 2008). In brief, the NESDA 
cohort (N=2981) consists of subjects (18­65 years) with (i) a current anxiety and/or 
depressive disorder, (ii) a prior history of a depressive and/or anxiety disorder and (iii) 
healthy controls. Subjects were recruited in primary care through a screening procedure, 
in specialized mental health care upon registration and in the community. All 2981 
subjects were administered a baseline assessment, which lasted on average 4h and 
included assessment of psychopathology, demographic and personal characteristics, 
psychosocial functioning, and biomarkers. Based on clinical judgment and if necessary 
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screening of the medical records, subjects with a primary diagnosis of psychotic disorder, 
obsessive­compulsive disorder, bipolar disorder, severe addiction disorder, and those not 
fluent in Dutch were excluded.  
 For the present study, we selected subjects with a lifetime history of major depressive 
disorder who did not fulfill the criteria for major depressive disorder in the six months 
preceding the baseline assessment, as recommended in a previous study (Furukawa et al., 
2008). An advantage of including people with remitted depression at baseline was that 
the measurement of life events, childhood trauma and cortisol levels was not influenced 
by the presence of a major depressive episode. This definition of MDD was based on the 
DSM­IV based Composite International Diagnostic Interview (CIDI), Lifetime Version 2.1 
(World Health Organization Lifetime Version 2.1, 1997). 810 participants met the criteria for 
a remitted MDD diagnosis. We excluded pregnant and breastfeeding women (n=6) as 
they may have altered cortisol levels. We did not take into account the timing of the 
menstrual cycle because in a previous study performed with NESDA data (Vreeburg et al., 
2009(a)) this was shown not to be associated to cortisol levels. None of the subjects used 
corticosteroid derivates. Furthermore, 34 subjects were excluded because their diagnosis 
was changed to bipolar disorder at follow­up, which puts them at a different recurrence 
risk level. Of the 770 subjects who met the criteria, 702 were re­interviewed at least once, 
either at the two­ or four­year follow­up assessment. After attrition, the sample ‘at risk’ for 
recurrence of MDD consisted of 702 subjects. Of these, 549 (78.2%) subjects had usable 
saliva samples to contribute to at least one of the saliva cortisol analyses and they 
constitute the present study sample. 
 These 549 subjects were older in comparison with the 261 subjects who were excluded 
from the present study sample (mean age 45.0 versus 40.5, p<0.001), but they did not 
differ in sex, educational attainment or number of previous episodes of MDD. 
Time to recurrence of MDD
Recurrence of MDD was assessed prospectively at two and four year follow­up using the 
CIDI, which measured the 1­month, 6­month, 1­year and 2­year prevalence of depression. 
To assess time to recurrence, the average within a certain period of prevalence was taken. 
Time from baseline to recurrence was calculated on the basis of this data. So, eight time 
intervals were made (12, 18, 21, 23.5, 36, 42, 45, 47.5 months). For example, if the respondent 
had a 1­month prevalence of MDD after two years, it was estimated that the time to 
recurrence from baseline was 23.5 months (24 minus 0.5 months). This represents the time 
to the first new major depressive episode (MDE). If the respondent had multiple episodes 
during follow­up the time from baseline to the first recurrence was taken.
Cortisol assessments  
Cortisol measurements have been described previously (Vreeburg et al., 2009a). In short, 
cortisol was measured through saliva sampling, reflecting the active unbound form of 
70
Chapter 5
cortisol (Kirschbaum & Hellhammer, 1989). Subjects were instructed to collect saliva 
samples at home shortly after the interview. Saliva samples were obtained using cotton 
salivettes (Sarstedt, Germany) seven times during the day. The cortisol awakening response 
includes four sampling points; upon awakening (t1), and 30 (t2), 45 (t3) and 60 (t4) minutes 
thereafter. Evening cortisol values were collected at 2200h (t5) and 2300h (t6). Dexa­ 
methasone suppression was measured using cortisol sampling the next morning upon 
awakening (t7) after ingestion of 0.5 mg dexamethasone directly after the saliva sample of 
2300h (t6). Samples were centrifuged at 2000g for 10 minutes, aliquoted and stored at 
­80oC. The analysis of cortisol was performed using competitive eletrochemiluminescence 
immunoassay (E170; Roche, Basel, Switzerland) as described by van Aken et al. (2003). 
The functional detection limit was 2.0 nmol/l and the intra­ and inter­assay variability 
coefficients in the measuring range were less than 10%. Assays were repeated if cortisol 
levels were very high (>80 nmol/l) or very low (<1 nmol/l). Data cleaning was performed 
by excluding cortisol values higher than two standard deviations (SD) from the mean (47 
of 3813 values). Additionally for CAR analysis, morning cortisol samples were excluded 
which were collected more than 5 minutes before or after the right protocol time (132 of 
2170 values).  
 Three cortisol indicators were calculated: the CAR, the evening cortisol level, and the 
DST. The CAR was assessed by calculating the area under the curve with reference to the 
increase (AUCi) and the ground/zero (AUCg) using Pruessner’s formulas (Pruessner et al., 
2003). The AUCg measures total cortisol secretion during the first hour after awakening 
and estimates total body exposure to cortisol. The AUCi measures cortisol increase with 
respect to awakening and is therefore a measure of the dynamics of the CAR, related to 
the sensitivity of the system and change in cortisol exposure over time (Clow et al., 2010). 
As the two evening cortisol values are strongly correlated (Spearman’s rho = 0.71, p<0.001), 
we used the mean of both cortisol levels as a measure of evening cortisol, which reflects 
basal activity. The DST provides information on the negative feedback system of the 
HPA­axis, since dexamethasone reduces cortisol levels by acting on the pituitary (Carroll et 
al., 1981). We calculated a cortisol suppression ratio by dividing the cortisol value at T1 by 
the value at T7 the following morning. 
Covariates
Based on previous studies (Burcusa & Iacono, 2007; Vreeburg et al., 2009a; Hardeveld et al., 
2010), various factors with the potential to predict MDD recurrence and salivary cortisol 
levels were assessed at baseline. 
Socio-demographic factors: Sex; age.
Clinical factors: Number of previous episodes (MDEs), categorized into single versus 
recurrent episodes. Anxiety disorders (social phobia, panic disorder with/without agoraphobia, 
agoraphobia, and generalized anxiety disorder) in the six months preceding baseline 
assessment were deemed to constitute relevant comorbid disorders. Severity of residual 
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symptoms of depression was measured with the inventory of depressive symptoms (IDS) 
(Rush et al., 1996); because cortisol levels could be state dependent (Stetler & Miller, 2011), 
we adjusted for residual depressive symptoms. History of depression in first­degree family 
members was assessed using a family tree inventory (Fyer & Weissman, 1999), categorized 
into ‘yes’ and ‘’no’.  
Stress related factors: Negative life events over the past year were assessed with the 
Brugha questionnaire (Brugha et al., 1985) which included 12 specific events and one 
‘other’ category asking about other serious negative life events (sum score ranging from 0 
to 5). The number of life events in the past year was calculated. In order to examine the 
role of childhood trauma, a cumulative childhood index using the NEMESIS childhood 
trauma interview was constructed (De Graaf et al., 2004; Wiersma, 2009; Hovens et al., 
2010). Participants were asked four questions regarding childhood experiences of 
emotional neglect, and emotional, physical and sexual abuse. A cumulative index was 
calculated as the sum of the number and frequency of the four types of abuse for each 
participant (sum score ranging from 0 to 8) in line with earlier studies (Wiersma, 2009; 
Hovens et al., 2010). 
Sampling factors associated with cortisol levels: Vreeburg et al. (2009a) established 
sampling factors relevant for HPA­axis indicators in our study: smoking (current or 
nonsmoker); awakening time; working day (yes, no). Presence of cardiovascular disease 
was established with an algorithm based on self­report and medication use, categorized 
into ‘yes’ and ‘’no’. 
Treatment: Pharmacological treatment was assessed based on inspection of the 
medication boxes used in the past month and coded using the WHO Anatomical 
Therapeutic Chemical (ATC) classification (REF to URL). Regular use of antidepressants was 
categorized into selective serotonin reuptake inhibitors (ATC­code N06AB), tricyclic anti­
depressants (ATC­code N06AA) or other antidepressants (ATC­code N06AF/N06AX). 
Sociodemographic, clinical, sampling factors and use of antidepressants were set as 
potential confounders. The stress related factors (childhood trauma and number of life 
events in past year) were set as potential effect modifiers (Shea et al., 2005; Rao et al., 2010; 
Morris et al., 2012). In a previous study performed with NESDA data (Holleman et al., 2012) 
stress related factors were found not to be associated to HPA­axis parameters and they 
were therefore not further considered potential confounders in our study. 
Statistical analyses
T­tests and X2­ square tests were performed to compare recurrent and non­recurrent 
subjects on baseline characteristics. The associations between HPA­axis parameters and 
risk for MDD recurrence over the course of the four year follow­up were analyzed using 
Cox regression analyses. The independent variables were the HPA­axis parameters, time to 
recurrence of depression was the dependent variable which was expressed in months 
and based on the CIDI. Hazard ratios and their 95% confidence intervals (95% CI) were 
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calculated, adjusted for covariates. The covariates were entered in blocks; sociodemo­
graphic factors, sampling factors and treatment with antidepressants in the first block, 
and clinical factors in the second block. As previous studies identified both hyperactivity 
and hypoactivity as predictors of MDD recurrence, we checked for potential non­linear 
associations by dividing the HPA axis parameters into quintiles. Linear mixed model 
analyses (LMM) were performed for the four morning cortisol measurements. LMM 
analyses can accommodate for incomplete cases and takes correlations between repeated 
measurements into account (Gueorguieva & Krystal, 2004). Therefore, LMM analysis 
included all subjects with at least two valid CAR values. In this analysis, recurrence of MDD, 
morning cortisol moments and all covariates were entered as fixed factors. Recurrence of 
MDD during follow­up was operationalized dichotomously (yes/no). Subjects were 
treated as a random effect and a random intercept was estimated. Recurrence of 
depression was the independent variable and the various morning cortisol levels were 
entered as the dependent variables. This analysis was used as a confirmation of the results 
of the Cox regression analysis. Furthermore, we checked whether interactions between 
stress­related factors (childhood trauma, number of life events in past year) and the 
HPA­axis parameters (CAR, DST, evening cortisol) were associated with the risk for MDD 
recurrence. Interaction terms were calculated by multiplying the stress­related factors by 
the different HPA­axis parameters which were centered because they were continuous. 
So, eight interaction terms were assessed. p Values ≤0.05 were deemed to be statistically 
significant for main effects and p values ≤0.10 for interaction terms.
5.3.  Results
Characteristics of the 549 subjects are presented in Table 1. 
 Of these, 392 subjects (71.4%) were female and the mean age was 45.0 years. The 
mean number of previous episodes of MDD was 2.9; 484 subjects (88.2%) remitted more 
than 12 months ago and 227 (41.3%) had no depressive symptoms in the five years 
preceding baseline which was assessed with the life chart interview (Lyketsos et al., 1994). 
During the four year follow­up, 131 subjects (23.9%) experienced a recurrence of MDD 
over the first two years, and 193 (35.2%) over the course of the four year follow­up. Mean 
time to recurrence was 27.4 months (sd=12.1).  Subjects who experienced a recurrence 
(n=193) during the 4­year follow­up were more often younger, more likely to have a history 
of more than one episode of depression at baseline, more often had a 6­month comorbid 
anxiety disorder at baseline, had more severe depressive symptoms at baseline, a higher 
number of traumatic youth experiences, used antidepressants more frequently, and had a 
higher AUCi. There were no differences between recurrent and non­recurrent subjects in 
sex, number of negative life events in the past year, family history of depression and 
covariates related to cortisol levels. 
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Table 1   Characteristics of 549 subjects divided in recurrence versus non recurrence  
of MDD during follow­up 
No recurrence 
(n=356)
Recurrence 
(n=193)
p
Socio-demographic factors
Gender, n (% female) 248 (69.7) 144 (74.6) 0.22
Age,  mean yrs (sd) 45.9 (12.6) 43.4 (12.0) 0.03
Clinical factors
History of MDEs, n (%) 158 (44.4) 109 (56.5) <0.01
6­Month anxiety disorder, n (%) 98 (27.5) 86 (44.6) <0.001
Severity of depressive symptoms (IDS), mean (sd) 15.0 (9.5) 21.2 (9.5) <0.001
Family history of depression, n (%) 287 (80.6) 164 (85.0) 0.20
Stress related factors
Trauma before age 16, n (%) 167 (60.3) 110 (39.6) 0.02
Trauma before age 16 index, mean score (sd) 0.8 (1.1) 1.1(1.2) 0.01
Number of negative life events, mean (sd) 0.5 (0.8) 0.5 (0.8) 0.62
Covariates related to cortisol levels
Smoking, n (%) 125 (35.1) 68 (35.2) 0.98
Time of awakening, mean hour (sd) 7:29 (1:04) 7:28 (1:05) 0.82
Cardiovascular disease, n (%) 14 (3.9) 6 (4.1) 0.90
Working on day of sampling, n (%) 230 (64.6) 119 (61.7) 0.49
Treatment
Use of antidepressants, n (%) 63 (17.7) 59 (30.6) 0.001
Cortisol 
AUCi (n=399), nmol/l/h (sd) 2.3 (6.3) 3.9 (6.5) 0.02
AUCg (n=399), nmol/l/h (sd) 19.0 (6.5) 19.7 (7.5) 0.34
DST (n=345), mean (sd)1 2.72 (1.37) 2.54 (1.09) 0.22
Mean evening cortisol  (n=546), nmol/l (sd)2 5.6 (4.4) 5.6 (4.0) 0.93
Abbreviations: MDEs=major depressive episodes, IDS=inventory of depressive symptoms, AUCi/AUCg=area 
under the curve with respect to the curve with respect to the increase/ground, DST= dexamethasone 
suppression test, mean evening cortisol.
1 DST= salivary cortisol at T1/cortisol level at T7 after 0.5 mg of dexamethasone ingestion.
2  mean evening cortisol=mean cortisol at T5 and T6.
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 A Cox regression analysis was performed, adjusted for covariates. Fully adjusted 
results illustrate that a higher AUCi is associated with time to recurrence of MDD (HR 1.03, 
95%CI 1.003­1.060, p=0.03) (Table 2). These results were also confirmed by LMM analyses 
(direct effect: p=0.10, interaction with time: p=0.05; Fig. 1). 
Evening cortisol levels and cortisol suppression after dexamethasone ingestion were not 
related to time to recurrence. The hazard ratios were constant over time. This was checked 
by calculating the different interaction terms (HPA­axis parameter x time) which were not 
statistically significant. 
Figure 1   Baseline 1­hour cortisol awakening levels for subjects with and without a 
recurrence of depression after four years based on linear mixed model analyses
Error bars illustrate 95% CI. Analyses are adjusted for gender, age, smoking, time of awakening, 
cardiovascular disease, working day, use of antidepressants, history of major depressive episodes, 
6­month prevalence of anxiety disorder, severity of depressive symptoms and family history of 
depression.
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 To analyze whether higher as well as lower cortisol levels were related to time to 
recurrence, we divided the HPA­axis parameters into quintiles, resulting into five categories. 
The middle quintile was the reference category. Table 2 shows that the highest AUCi, fully 
Table 2   Recurrence of MDD across various salivary cortisol indicators adjusted  
for covariates 
HR (95% CI)* p HR (95% CI)** p
AUCg (nmol/l/hour) (n=399)
Continuous  
<13.68
13.68­16.63
16.64­19.73
19.74­24.30
>24.30
1.02 (1.00­1.05)
1.19 (0.68­2.09)
0.94 (0.51­1.70)
ref
1.52 (0.88­2.63)
1.46 (0.80­2.47)
0.08
0.55
0.85
ref
0.13
0.24
1.03 (1.00­1.05)
1.27 (0.72­2.26)
0.90 (0.50­1.62)
ref
1.49 (0.86­2.58)
1.40 (0.79­2.47)
0.08
0.41
0.72
ref
0.15
0.25
AUCi (nmol/l/hour) (n=399)
Continuous
<­2.15
­2.15­0.95
0.96­3.84
3.85­7.00
>7.00
1.03 (1.003­1.060)
1.14 (0.61­2.20)
1.34 (0.75­2.40)
ref
1.33 (0.75­2.36)
1.90 (1.08­3.33)
0.03
0.69
0.32
ref
0.34
0.03
1.03 (1.004­1.059)
1.03 (0.55­1.92)
1.38 (0.76­2.50)
ref
1.27 (0.71­2.27)
1.81 (1.02­3.21)
0.03
0.94
0.29
ref
0.43
0.04
DST1 (n=345)
Continuous
<1.69
1.69­2.21
2.22­2.65
2.66­3.27
>3.27
0.92 (0.79­1.07)
1.19 (0.68­2.08)
0.67 (0.37­1.24)
ref
1.19 (0.69­2.05)
0.71 (0.39­1.30)
0.28
0.54
0.20
ref
0.54
0.27
0.93 (0.80­1.08)
1.18 (0.67­2.08)
0.79 (0.43­1.46)
ref
1.24 (0.72­2.16)
0.79 (0.43­1.44)
0.32
0.56
0.45
ref
0.44
0.43
Mean evening cortisol2  (n=546)
Continuous 
<3.10
3.10­4.42
4.43­5.57
5.58­7.11
>7.11
0.99 (0.96­1.03)
0.82 (0.52­1.29)
0.78 (0.50­1.23)
ref
0.95 (0.61­1.47)
0.88 (0.56­1.39)
0.67
0.39
0.29
ref
0.81
0.59
0.99 (0.96­1.02)
0.81 (0.52­1.27)
0.73 (0.46­1.16)
ref
0.94 (0.60­1.47)
0.83 (0.52­1.31)
0.46
0.35
0.19
ref
0.78
0.42
Abbreviations: HR=hazard ratio, CI= confidence interval, AUCi/AUCg area under de curve with respect to the 
increase/ground,  DST=dexamethasone suppression test, ref=reference category. 
In bold: statistically significant. 
* Based on Cox’s survival analyses and  adjusted for gender, age, smoking, time of awakening, cardiovascular 
disease, working day, use of antidepressants. ** Based on Cox’s survival analyses and adjusted for gender, age, 
smoking, time of awakening, cardiovascular disease, working day, use of antidepressants, history of major 
depressive episodes, 6­month prevalence of anxiety disorder, severity of depressive symptoms and family 
history of depression.
1 DST= salivary cortisol at T1/cortisol level at T7 after 0.5 mg of dexamethasone ingestion
2  mean evening cortisol=mean cortisol at T5 and T6.
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adjusted for covariates, was associated with recurrence (HR 1.81, 95% CI 1.02­3.21, p=0.04). 
AUCg, evening cortisol and DST were also divided into quintiles. No difference in risk for 
MDD between low and high cortisol levels was found for these HPA­axis parameters. In 
the fully adjusted Cox regression model, we checked whether the stress related factors 
(childhood trauma and number of life events in past year) and the HPA axis parameters 
(AUCi, AUCg, DST, mean evening cortisol) interacted by entering the interaction term 
separately into the model (8 interactions). However, no statistically significant interaction 
terms were found (p interaction>0.10). 
5.4.  Discussion
The aim of this study was to examine whether HPA­axis parameters are related to risk for 
MDD recurrence among subjects who had recovered from a previous episode of MDD. 
We found that a higher cortisol awakening response was associated with time to 
recurrence of MDD. Hypocortisolism was not related to recurrence and we did not find 
any associations with other HPA­axis parameters (DST and evening cortisol). Furthermore, 
no significant interactions between HPA axis parameters and stress related factors were 
found. This indicates that the increased risk for a recurrence of depression due to a high 
CAR is not dependent on recent life events or childhood trauma.
 Our study supports the predictive role of a higher CAR in recurrence of depression, in 
line with previous studies which also found that hyperactivity was related to recurrence of 
MDD (Ribeiro et al., 1993; Zobel et al., 1999; Harris et al., 2000; Zobel et al., 2001; Hatzinger 
et al., 2002; Appelhof et al., 2006; Aubry et al., 2007; Bhagwagar et al., 2008; Pintor et al., 
2009; Vrshek­Schallhorn et al., 2013). The study by Vrshek­Schallborn et al. (2013) is the most 
similar to our study and also found a higher CAR to be related to recurrence. One study 
(Bockting et al., 2012) found decreased mean morning cortisol levels to be predictive of 
recurrence. In line with Bocking et al. (2012) a recent NESDA study (Vreeburg et al., 2013) 
found that a lower CAR in persons with a current depressive and/or anxiety disorder was 
associated with an unfavorable prognosis for cases without remission longer than 3 
months. Such discrepancies may be explained by the fact that we did not study subjects 
with multiple episodes in the recent past but those who had an major depressive episode 
further in the past. Bockting et al. (2012) included subjects with at least two major 
depressive episodes in the last five years. In our study sample, 41.3% had no depressive 
symptoms in the five years preceding baseline and only 51.4% of the subjects had one 
MDE in the past, indicating that subjects in our study sample did not have a chronic 
recurrent course in the recent past. Thus, while our data suggest that a higher CAR is 
associated with MDD recurrence in remitted depressed patients, previous studies also 
based on NESDA data postulate that a lower CAR is associated with chronicity of MDD in 
currently depressed patients data (Vreeburg et al., 2013). A possible explanation for such 
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discrepancies is that chronic stress or duration of symptoms of depression may lead 
initially to HPA axis hyperactivity and over time to down­regulation of glucocorticoid and 
mineralocorticoid receptors, resulting in hypocortisolism (Buchanan et al., 2004; Pruessner 
et al., 2007). It has been argued that a higher CAR represents a ‘trait’ marker for recurrence 
of depression whereas a lower CAR can be identified as a ‘scar’ marker for current 
depression (Vreeburg et al., 2013). Thus, a high AUCi may also represent a trait marker for 
recurrence of depression. This is in line with previous studies. A recent study (Vrshek­Schall­
born et al., 2013) concluded that a higher CAR also predicted first onset. Furthermore, the 
CAR is higher in young people who have not been depressed themselves but have a 
family history of depression (Mannie et al., 2007; Vreeburg et al., 2010) and a recent study 
also using data of NESDA did suggest that cortisol levels were not convincingly associated 
with childhood trauma (Holleman et al., 2012). Besides, Lok et al. (2012) found that remitted 
highly recurrent MDD patients had higher cortisol concentrations than controls which 
was not influenced by MDD­episodes during follow­up and HPA axis activity had no 
association with daily hassles or childhood life events. These data could suggest a genetic 
vulnerability trait. A previous study (Wϋst et al., 2000) also concluded that there is a 
significant genetic influence on the CAR. It could be that in those in remission for a long 
time who are not exposed to high stress levels the HPA­axis activity returns to the original 
level prior to the depression. Hyperactivity of the HPA­axis could function as a risk factor 
as before a first episode. Interestingly, the study by Vrshek­Schallhorn et al. (2013) found 
that the CAR was a time­limited risk factor and predicted recurrences of depression with 
greater strength than it predicted a first episode. However, in our study the number of 
prior major depressive episodes experienced did not interact with CAR to predict time to 
recurrence. 
 Despite a large number of studies on the CAR, the exact function of the sharp cortisol 
increase after awakening is still unknown. Fries et al. (2009) hypothesized that “the cortisol 
rise after awakening may accompany an activation of prospective memory representa­
tions at awakening enabling individual’s orientation about the self in time and space as 
well as anticipation of demands of the upcoming day, with an important role for the 
hippocampus”. In our study, the AUCi was associated with recurrence of depression which 
is a measure of the dynamics of the CAR, related to the sensitivity of the system (Clow et 
al., 2010). Therefore, our data provides some indications that the sensitivity of the HPA­axis 
could play a role in the risk for recurrence, whereas the total amount of cortisol during the 
day or the negative feedback mechanism as evening cortisol and DST were not related to 
recurrence. An alternative hypothesis is that the CAR is more sensitive to moderate 
degrees of depression than the DST, e.g. failure to suppress to dexamethasone is associated 
with more severe depression such as melancholia and inpatient status (Nelson & Davis, 
1997). Although there is no use of the CAR as a diagnostic tool or biomarker in a clinical 
setting so far, it is a valuable instrument in research on stress­related disorders such as 
MDD. It remains to be seen whether a higher AUCi is an epiphenomenon or plays a 
78
Chapter 5
substantial role in the onset or course of a depressive episode. A hypothesis could be that 
a higher CAR reflects a marker for increased sensitivity for (psychosocial) stress which is 
associated with an increased risk for a recurrence. Though, our analyses did not support 
this assumption as the CAR did not interact with stressful life events in increasing the risk 
for a recurrence. However, it is important to note that the stressful life events measures 
were assessed for the time period prior to baseline assessment.    
 The strengths of our study are that we were able to examine several HPA axis 
parameters and take into account important covariates in a large representative sample 
using standardized instruments to determine diagnosis and course. It should be 
mentioned that our results are restricted to those without a chronic recurrent course of 
depression in the recent past as 41.3% of our study sample had no depressive symptoms 
in the five years preceding baseline. Furthermore, the HPA­axis has an diurnal rhythm, and 
although we took the morning awakening response into account, by creating the area 
under curve to the ground and to the increase and measured evening cortisol levels we 
could not determine a more precise diurnal rhythm during the day since we did not 
collect mid­day cortisol levels.  We could have created diurnal rhythm, by extracting the 
evening curve levels from the morning curve levels. However, the resulting diurnal variable 
is highly correlated to the morning curve levels. This is due to the fact that the evening 
levels are generally much lower than the morning curve levels, causing the height of the 
morning curve levels to heavily determine the diurnal rhythm variable. We also had 
missing data in our study sample largely because we had no information on cortisol 
values at baseline of these subjects. Selection was not at random as the study sample was 
older in comparison with the subjects who were excluded from the study (mean age 45.0 
versus 40.5, p<0.001). They did however not differ in sex, educational attainment or 
number of previous episodes of MDD. Nevertheless, our sample seems representative for 
an outpatient treated group. When interpreting the results of this study, its limitations 
should also be taken into account. First, time to recurrence of depression was measured 
during follow­up with the use of the prevalence rates at 2­ and 4 years. The estimated time 
to recurrence was measured with the averages of these prevalence rates (see method 
section) which may not be completely accurate to assess time to recurrence. Time to 
recurrence could therefore be overestimated. Also, lifetime diagnoses of depression were 
assessed retrospectively and could be affected by recall bias. Second, the subjects’ state 
of depressive symptoms may lead to unreliable results of HPA­axis values. Although they 
were all in remission for at least six months some subjects may be in a recurrence for a 
rather short period, others for a more extended period of time. Although subjects were in 
remission as confirmed by the CIDI psychiatric interview, subjects could experience 
residual symptoms at baseline. The mean IDS score in our study sample was 17.2 (s.d.=9.9). 
The IDS could affect HPA­axis parameters. We, however, adjusted for the IDS score in the 
final model which did change the results only slightly and examined possible interaction 
effects of IDS with HPA­axis parameters which were not found. Also, physical diseases 
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could affect the HPA­axis values which we did not exclude specifically. We, however, 
excluded pregnant and breastfeeding women, those who used corticosteroid derivates 
and adjusted for health indicators which in a previous NESDA study (Vreeburg et al., 2009a) 
have been found to be associated with HPA­axis parameters. We also excluded those with 
cortisol values two standard deviations above the mean. Furthermore, we did not measure 
current stress levels or state effects (such as variations in mood, sleep, etc.) on the exact 
day of saliva sampling. Although we instructed subjects to collect the samples on a 
representative day without unusual amounts of stress, state effects could have played a 
role. Sampling on multiple days would have increased the reliability of the measurements 
(Hellhammer et al., 2007). However, the large sample size of our study may have partly of 
fully compensated for this.  Finally, our study was based on observational data, so no 
causal association between cortisol levels and recurrence of MDD can be drawn. 
 In conclusion, this study shows that a higher cortisol awakening response, related to 
the sensitivity of the HPA­axis, increases vulnerability to new depression episodes, even if 
a subject has been in remission for a long period. Neither the DST or evening cortisol 
levels were associated with recurrence and the higher risk for recurrence related to a high 
CAR was not dependent on stressful life events. Further research should investigate the 
CAR in association with the course of depression over time to distinguish possible 
depression trajectories in association with the HPA­axis.
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Abstract 
Objective: Previous research found that variants of the glucocorticoid receptor (GR) (9ß, 
ER22/23EK, BclI, TthIIIl, NR3C1­1 and N363S) and mineralocorticoid receptor (MR) gene 
polymorphism (­2C/G and I180V) are associated with both glucocorticoid (GC) sensitivity 
and major depressive disorder (MDD). There are no data which investigated prospectively 
whether these variants are associated with recurrence of MDD.  
Methods: Data were derived from the Netherlands Study of Depression and Anxiety 
(NESDA) which used the Composite International Diagnostic Interview (CIDI) to determine 
MDD. Polymorphisms in the GR and MR gene were determined and haplotypes were 
characterized. We analysed in retrospect whether recurrent MDD (n=951) in comparison 
with first onset MDD (n=919) was associated with polymorphisms in the GR and MR gene. 
Furthermore, we analysed prospectively for four years the time to recurrence amongst 
683 subjects with a remitted MDD diagnosis. Time to recurrence of MDD was assessed 
using the CIDI and a life chart interview. Additionally, we analysed interactions of the 
investigated polymorphisms with childhood trauma and recent negative life events.  
Results: GR and MR gene polymorphisms and derived haplotypes were not associated 
with recurrence of depression in both retrospective and prospective analyses. In addition, 
no consistent interactions between GR and MR polymorphisms and childhood trauma or 
life events were found. 
Conclusion: This study did not find consistent associations between GR and MR gene 
polymorphisms, interactions between GR and MR haplotypes and stressful conditions 
and recurrence of MDD.
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6.1.  Introduction
Major depressive disorder (MDD) is one of the disorders with the highest morbidity 
worldwide (World Health Organisation, 2008) and long term strategies aimed at reducing 
recurrence could be an effective way to reduce the population burden of MDD (Vos et al., 
2004). However, knowledge of the predictors of recurrence is still sparse. MDD is a complex 
disorder that does not result from either genetic or environmental influences alone but 
rather from both. 
 A possible link between environmental influences, e.g. stressful conditions, genetic 
risk factors and the risk for a recurrence of MDD could be an altered function of the hypo­
thalamic­pituitary­adrenal (HPA) axis. In reaction to stressful conditions, glucocorticoids 
coordinate metabolic, endocrine, immune and nervous system responses. Recurrences of 
MDD are associated with childhood trauma (Hardeveld et al., 2013), recent life events 
(Monroe et al., 2014) and HPA­axis alterations (Ribeiro et al., 1993; Zobel et al., 1999; Harris 
et al., 2000; Zobel et al., 2001; Hatzinger et al., 2002; Bhagwagar et al., 2003; Appelhof et al., 
2006; Aubry et al., 2007; Bhagwagar and Cohen, 2008; Pintor et al., 2009; Rao et al., 2010; 
Bockting et al., 2012; Vrshek­Schallhorn et al., 2013). It has been postulated that childhood 
trauma can induce persistent changes in the response of the HPA axis, which can become 
apparent when persons are exposed to psychosocial stressors in adulthood (Von Werne 
Baes et al., 2012; Juruena, 2014). A recent study (Hardeveld et al., 2014) published in this 
Journal concluded that the cortisol awakening response was associated with time to 
recurrence of MDD and it was postulated that an increased cortisol awakening response 
could also be a genetic vulnerability trait. The effects of glucocorticoids are mediated by 
the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) and altered 
sensitivity to glucocorticoids of both receptors could lead to reduced negative feedback 
of cortisol, an increased production of corticotrophin releasing factor and consequently 
hypercortisolism which has been associated with the pathophysiology of MDD 
(glucocorticoid cascade hypothesis) (Nemeroff, 1996; Holsboer, 2000; Pariante, 2009). 
Sensitivity to glucocorticoids varies between individuals (Stevens et al., 2004) and various 
common single nucleotide polymorphisms (SNPs) are associated with glucocorticoid 
sensitivity (Spijker and van Rossum, 2012). For the MR gene these are: ­2 G/C and I180V (De 
Rijk et al., 2006; van Leeuwen et al., 2011) and for the GR gene these are: 22/23 EK, 9β, 
N363S, TthIIIl, NR3C1­1, and BclI (Huizinga et al., 1998; van Rossum et al., 2002; van Rossum 
et al., 2003; Wüst et al., 2004; Spijker et al., 2012). Studies also found that these polymorphisms 
were associated with onset and presence of major depression (van Rossum et al., 2006; 
van West et al., 2006; Kuningas et al., 2007; Zobel et al., 2008; Krishamurthy et al., 2008; Bet 
et al.,2009; Otte et al., 2009; Klok et al., 2011; Spijker and van Rossum, 2012; Szczepankiewicz 
et al., 2011; Galecka et al., 2013). Three studies examined recurrent MDD versus controls in 
retrospect (van West et al., 2006; Zobel et al, 2008; Galecka et al., 2013) and found that 
N363s, BclI and 22/23 EK were associated with recurrent MDD. Only one study (Bet et al., 
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2009) investigated interactions and found that an interaction between the GR poly ­
morphisms 22/23 EK and 9β and childhood trauma resulted in an increased risk for 
developing depressive symptoms at old age. To the best of our knowledge, there is no 
research which investigated prospectively whether these variants are associated with 
recurrence of MDD.
 We aimed to investigate retrospectively as well as prospectively whether the SNPs 
located on the GR and MR which are associated with glucocorticoid sensitivity and MDD 
are also associated with recurrence of MDD. Furthermore, we investigated whether these 
SNPs interact with stressful conditions (childhood trauma, life events). Our hypothesis was 
that polymorphisms of the GR and MR gene associated with glucocorticoid sensitivity and 
depression increase the risk of a recurrent course of depression or a faster time to 
recurrence. Moreover, we hypothesized that these polymorphisms interact with stressful 
conditions (childhood trauma, recent life events), increasing the risk for a recurrence. 
6.2.  Methods
Study sample
Data were from the Netherlands Study of Depression and Anxiety (NESDA), a prospective 
cohort study investigating the long­term course of depressive and anxiety disorders. At 
baseline, 2981 subjects (18­65 years) were recruited in primary care, in specialized mental 
health care and in the community. The study protocol was approved by the Ethical 
Committee of participating universities. All subjects provided written informed consent. 
The rationale, objectives, and methods of NESDA have been described in detail elsewhere 
(Penninx et al., 2008). In brief, the NESDA cohort (N=2981) consists of subjects (18­65 years) 
with (i) a current anxiety and/or depressive disorder, (ii) a prior history of a depressive and/
or anxiety disorder and (iii) healthy controls. Subjects were recruited in primary care 
through a screening procedure, in specialized mental health care upon registration and in 
the community. All 2981 subjects were administered a baseline assessment, which lasted 
on average 4h and included assessment of psychopathology, demographic and personal 
characteristics, psychosocial functioning, and biomarkers. Based on clinical judgment and 
if necessary screening of the medical records, subjects with a primary diagnosis of 
psychotic disorder, obsessive­compulsive disorder, bipolar disorder, severe addiction 
disorder, and those not fluent in Dutch were excluded. All subjects were from North­
ern­European ancestry. 
 For our present study, the first four years were used. We selected subjects with a 
lifetime history of MDD (n=1925). The diagnosis was assessed at baseline and based on the 
DSM­IV based Composite International Diagnostic Interview (CIDI), lifetime version 2.1. Of 
these, 55 subjects were excluded because they did not have DNA data or that the samples 
of these subjects did not pass basic quality control (see GR and MR variants section). 
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Subjects with or without DNA data did not differ in age, sex or history of recurrent MDD. 
We applied two different analytic approaches. First, we analysed in retrospect whether 
subjects with GR and MR polymorphisms associated with glucocorticoid sensitivity more 
often had a recurrent MDD (n=951) as compared to those having a single episode (n=919). 
Second, in a more stricter approach we selected those who were in remission of MDD for 
at least six months preceding the baseline assessment and assessed time to recurrence 
prospectively during four years using the life chart interview (LCI) (Lyketsos et al., 1994). 
The LCI uses age­ and calendar­linked personal landmarks to describe time sequence of 
symptoms of MDD. In this way, it was possible to assess time to recurrence of MDD per 
month follow­up. Recurrence was defined as recurrence of symptoms after remission to 
at least mild severity level persisting for at least one month with the additional criterion 
that a CIDI­confirmed MDD diagnosis was present during follow­up. 810 subjects fulfilled 
the definition of a remitted MDD diagnosis. Of these, 18 subjects were excluded because 
these subjects did not collect DNA data or the DNA samples did not pass basic quality 
control. 80 subjects (10.1%) were excluded because they did not have a (complete) LCI 
during follow­up or were lost to follow­up. Drop­out was associated with lower educational 
attainment (F=1.99, p=0.05), but not with sex or age. Finally, 29 subjects were excluded 
because the diagnosis changed to bipolar disorder during follow­up. Consequently, in 
683 subjects GR and MR polymorphisms could be analysed prospectively for recurrence 
of MDD.  
GR and MR variants
For the present study, MR and GR SNPs were selected which in previous research were 
associated with glucocorticoid sensitivity (Spijker et al., 2012). For the GR gene these are: 
22/23 EK (rs6189/rs6190, GAGAGG>GAAAGG), 9ß (rs6198, A>G), N363S (rs56149945, 
previously coded rs6195, AAT>AGT), TthIIII  (rs10052957, C>T) NR3C1­1 (rs10482605, T>C) 
and BclI (rs41423247, C>G). For the MR gene these are: − 2 G/C (rs2070951, G>C) and I180V 
(rs5522, A>G). Genotyping of the SNPs was performed on two platforms: OpenArray® Real 
timePCR System (Life Technologies, Carlabad, USA) and Affymetrix 6.0 (Santa Clara CA; 
Perfegen 5.0, Mountain View, CA USA) which was imputed against the 1000 genomes (1KG 
Phase reference panel l release version 3 2012­03­14). Subjects were excluded based on a 
SNP genotype missing rate of > 10%, heterozygosity ­0.1 < F < 0.1 or when the X 
chromosome status did not match phenotype sex. Best guess genotype data was used 
based on a cut­off of 0.90. Allele frequencies lower than 1% were excluded. For the data 
retrieved from OpenArray® Real timePCR System, also samples with a call rate <  95% were 
removed. The retrieved SNP data were highly correlated (Pearson square>0.95). Because 
the number of usable DNA samples was larger in the Affymetrix 6.0 dataset, this dataset 
was used. An exception was ­2 G/C which could only be retrieved through OpenArray® 
Real timePCR System. 
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Stress related factors
We determined two types of stress related factors: negative life events in the last year and 
childhood trauma. Number of negative life events were determined with the Brugha 
questionnaire (Brugha et al., 1985) which included 12 specific events and one ‘other’ 
category asking about serious other negative life events. The number of life events in the 
past year was calculated. For childhood trauma a cumulative childhood index was 
constructed (Wiersma et al., 2009; Hovens et al., 2010) by asking four questions regarding 
the occurrence and frequency of childhood experiences of emotional neglect, or 
emotional, physical, or sexual abuse. A cumulative index was calculated as the sum of the 
number and frequency of the four types of abuse for each subject in line with earlier 
studies (Wiersma et al., 2009; Hovens et al., 2010).  
Covariates
Besides age and sex, pharmacological treatment was also considered a covariate based on 
previous studies (Brouwer et al., 2006; Anacker et al., 2011). This was assessed based on 
inspection of the medication boxes used in the past month and coded using the WHO 
Anatomical Therapeutic Chemical (ATC) classification (REF to URL). Regular use of anti­
depressants was categorized into selective serotonin reuptake inhibitors (ATC­code N06AB), 
tricyclic antidepressants (ATC­code N06AA) or other antidepressants (ATC­code N06AF/
N06AX). Use of antidepressants was dichotomized into yes or no. Furthermore, we took 
into account possible genetic variation in the Dutch population. An earlier study performed 
in NESDA (Abdellaoui et al., 2013) identified three principal components which showed 
significant correlations with geography, distinguishing between: North and South, East 
and West, and the middle­band and the rest of the Netherlands.     
Statistical Analyses
SNPs were tested for Hardy­Weinberg equilibrium. Haplotypes were created with Phase 
(http://stephenslab.uchicago.edu/software.html) (Stephens et al., 2001). For each haplotype 
three genotype combinations were distinguished carrying 0, 1, or 2 copies of the haplotype 
allele. Power calculations for the cross sectional (logistic regression) analyses were performed 
with Quanto version 1.2.4 (http://www.mybiosoftware.com/population­ genetics/5931), 
and indicated that for the SNP with the highest minor allele frequency (rs2070951) we 
could detect an OR of 1.13 with 80% power, this was OR=1.92 for the SNP with the lowest 
minor allele frequency (rs6189) (calculation of gene­effect only, unmatched case control 
ratio 1:1 and assuming a log additive model of inheritance). As recommended by Owzar 
et al. 2012, for the prospective (Cox proportional hazards model) analysis the software 
program R version 3.1.2 was used. Calculations indicated that for the SNP highest minor 
allele frequency (rs2070951) we could detect an HR of 1.29 with 80% power, this was 
HR=3.00 for the SNP with the lowest minor allele frequency (rs6189) (event rate=36.6%, 
landmark time=24 months, probability that time to event is greater than landmark time= 19.2%, 
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and assuming a log additive model). All other analyses were performed with SPSS version 
20.0. Subsequently, associations between GR and MR polymorphisms, its haplotypes and 
recurrence (recurrent versus single episode, time to recurrence) were analysed using 
multinomial logistic regression analyses and Cox regression analyses, adjusted for age, 
sex, principal components and treatment. Finally, we checked for interactions between 
GR and MR haplotypes and stress related factors. Interaction terms were calculated by 
multiplying the GR and MR haplotypes by the stress­related factors. So, nine different 
haplotypes were analysed with two different stress related factors (18 tests), in retrospect 
as well as prospectively. Bonferoni correction for multiple testing was performed for GR/
MR polymorphism analyses (16 tests, p<0.003), haplotype analyses (18 tests, p<0.003) and 
interaction terms (18 tests <0.003). 
6.3.  Results
Characteristics
As mentioned previously, we applied two different analytic approaches to assess recurrence. 
The characteristics are presented in Table 1. 
 Of the subjects (n=1870) which were analysed in retrospect 68.4% were female and 
the mean number of episodes of MDD was 3.4 (sd=3.9). 919 subjects (49.1%) had a first 
MDD and 50.9% had a recurrent MDD lifetime. As expected, the average age of the 
subjects was higher in those with a recurrent course (41.2 versus 42.8 years, p<0.01). In the 
longitudinal analyses (n=683) 48.8% (n=333) of the included subjects had a lifetime 
recurrent MDD and 36.6% (n=250) had a recurrence of MDD during follow­up. The mean 
time to recurrence was 11.8 months (sd=12.6). Subjects with a recurrence of MDD during 
follow­up more often had a childhood trauma (48.3% versus 57.3%, p=0.03) and used 
more often an antidepressant (17.3% versus 31.6%, p<0.001). Age and sex distributions did 
not differ among the GR and MR genotypes besides SNP ­2 G/C of which less females had 
a GG genotype in comparison with GC or CC (62.8 versus resp. 69.0 and 70.7, p=0.03). 
MR- and GR genotypes and haplotypes
Genotype distributions for all polymorphisms were in Hardy Weinberg equilibrium 
(Pearson square >0.05). The frequencies of the GR and MR SNPs are described in Table 2. 
 Notable, there were no individuals in our study sample carrying homozygote SNPs of 
rs6189/6190 TT and rs56149945 CC. Concordant with previous studies (van Winsen et al., 
2009; Spijker et al., 2011; Klok et al., 2011), six main haplotypes were found for GR and three 
for MR. Frequencies are displayed in Table 3. Both haplotypes of GR and MR (haplotypes 1) 
with the highest frequencies consisted of the major alleles of the measured SNPs. After 
post hoc Bonferroni correction for multiple testing (p<0.003), no associations between the 
GR and MR SNPs, its haplotypes and recurrence of depression were found (Table 2 and 3). 
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Also no consistent interaction terms (p<0.003) between stress related factor and GR/MR 
haplotypes were found (Table 4). Although non­significant after Bonferoni correction, 
there are results worth mentioning. Two copies of the haplotype characterized by the 
minor allele of ­2 C/G of the MR were associated with time to recurrence (HR=0.53, 95% 
CI=0.29­0.94, p=0.03) indicating a protective effect (Table 3). Subjects with two copies of 
the haplotype TCTCCAA (BclI,TthIIIl) of the GR had more often a recurrent course in 
comparison with those with one or zero copies (OR=2.75, 95% CI 1.07­7.03, p=0.04) (Table 3). 
Two copies of this haplotype was, on the other hand, also associated  with a longer time 
to recurrence (33.5 months versus 11.9 and 11.3, p=0.002). It should be noted that in this 
later analyses the number of subjects who had two copies of the haplotype 4 was only 
four. Also two interactions need to be addressed, GR haplotype CGTCCGA (9ß,NR3C1­1,T­
thIIIl) with childhood trauma (HR=0.74, 95%CI=0.60­0.92, p=0.01) and GR haplotype 
TGCCCAG (N363S) with recent life events (HR= 7.75, 95% CI, 1.07­56.10, p=0.04) because of 
the low p­values (see Table 4). However, considering the number of tests conducted and 
the inconsistency of the findings with contrasting findings in the retrospective and 
prospective analyses, we consider these chance findings. 
Table 1   Characteristics of the subjects in the retrospective and prospective cohort 
Life time MDD 
(n=1870)
Recurrence during follow-up  
(n=683)
First  
(n=919)
Recurrent 
(n=951)
p No recurrence  
(n=433)
Recurrence 
(n=250)
p
Socio-demographic factors
Female, n (%) 616 (67.0) 664 (69.8) 0.19 300 (69.3) 190 (76.0) 0.06
Age, mean yrs (sd) 41.2 (12.9) 42.8 (11.8) <0.01 44.4 (12.8) 42.6 (12.0) 0.07
Stress related factors
Childhood trauma, 
n (%)
513 (55.9) 558 (59.0) 0.18 210 (48.6) 142 (57.3) 0.03
Childhood trauma, 
mean (sd)
1.12 (1.23) 1.11 (1.17) 0.87 0.85 (1.07) 1.11 (1.22) 0.003
Life events in past 
year present, n (%)
403 (43.9) 379 (39.9) 0.08 144 (33.3) 96 (38.4) 0.18
Life events in past 
year, mean (sd)
0.75 (1.09) 0.64 (0.94) 0.02 0.50 (0.83) 0.54 (0.80) 0.50
Treatment
Use of anti­
depressants, n (%)
336 (36.3) 309 (32.5) 0.08 75 (17.3) 79 (31.6) <0.001
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Chapter 6
Our recent study (Hardeveld et al., 2014) published in this Journal concluded that the 
cortisol awakening response was associated with time to recurrence of MDD and it was 
postulated that an increased cortisol awakening response (CAR) could also be a genetic 
vulnerability trait. Therefore, we also investigated whether the CAR was associated with 
GR and MR polymorphisms in our study sample. The methods of the HPA­axis parameters 
measurements were described in our recent study (Hardeveld et al., 2014). For this analyses 
we used the baseline sample (n=2981). Eventually, 1211 subjects were included, after 
excluding invalid CAR data or DNA data. Using ANOVA, no associations between CAR and 
the investigated haplotypes were found. We also analysed a possible interaction of CAR 
by haplotype on time to recurrence (n=490). However, no interactions were found.  
6.4.  Discussion
 
This study did not find consistent associations between GR and MR polymorphisms, 
interactions with childhood trauma or recent life events and recurrence of MDD. So, our 
results suggest that these polymorphisms may be associated with onset and presence of 
MDD (van Rossum et al., 2006; van West et al., 2006; Kuningas et al., 2007; Zobel et al., 2008; 
Krishamurthy et al., 2008; Bet et al., 2009; Otte et al., 2009; Klok et al., 2011; Spijker et al., 2012; 
Szczepankiewicz et al., 2011; Galecka et al., 2013) but not with recurrence of MDD. Three 
studies examined recurrent MDD versus healthy controls in retrospect (van West et al., 
2006; Zobel et al, 2008; Galecka et al., 2013). So, these studies found that the investigated 
SNPs were associated with presence of recurrent MDD but these studies did not investigate 
recurrence of MDD versus first onset which makes a comparison with our study difficult. It 
should be noted that also negative results were found and none of the investigated SNPs 
were consistently confirmed in previous studies. 
 What could be explanations for our negative results? El Hage et al. (2009) postulated 
that gene environmental interactions in depression involves complex participation of 
serotonergic genes modulating responses to stress through the HPA­axis. Also modulating 
genes involved in the HPA­axis, for example FKPB5, may be associated with MDD risk (Spijker 
and van Rossum, 2012; Szczepankiewicz et al., 2014). El Hage et al. (2009) hypothesized that 
subjects with a low activity of 5­HTTLPR have elevated activity in the amygdala. A hyper active 
amygdala enhances HPA­axis functioning which could lead to sustained hypercortisolism 
which is associated with recurrence of MDD (Hardeveld et al., 2014). Whether sustained 
hypercortisolism will be present is also dependent on MR and GR expression which is 
modulated by FKPB5, amongst others. In our study the CAR was not associated with GR 
and MR haplotypes. So, it could be that in our sample GR and MR haplotypes did not, or 
only slightly, contribute to hypercortisolism and hereby did not increase the risk for a 
recurrence of MDD. Alternatively, interactions of GR and MR haplotypes with serotonergic 
or modulating genes of the HPA­axis may increase the risk for a recurrence.  
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 Although an earlier study using NESDA data (Holleman et al., 2012) did not convincingly 
find an association of HPA­axis parameters and childhood trauma, substantial evidence 
reviewed by Juruena  (2014) indicate that childhood trauma can induce changes in the 
ability of the HPA­axis to respond to stress in adulthood by reducing the ability of cortisol 
to bind to GR and MR. It was postulated that an imbalance in MR and GR functioning may 
be a risk factor for depression. This mechanism could also lead to an increased awakening 
response which we found to be associated with recurrence of MDD (Hardeveld et al., 
2014). The contribution of the GR and MR polymorphisms in epigenetic modification may 
be minor. 
 To our knowledge, this is the first study that investigated GR and MR polymorphisms 
and recurrence of MDD prospectively. We examined multiple GR and MR gene 
polymorphisms in a large sample and used standardized instruments to determine 
diagnosis and recurrence. However, there are a number of limitations. First, we did 
investigate candidate genes which were associated with glucocorticoid sensitivity and 
MDD but other SNPs located on the GR or MR gene could be involved in recurrence. We 
did not perform a whole gene­based association analysis of SNPs on the GR and MR. 
However, if we would have tested more SNPs, requirements for significance would have 
been more stringent with accompanying power issues. On the other hand, because we 
tested several SNPs Bonferonni correction had to be performed. If we would have tested 
less SNPs a significant result would have been found. Also, for some polymorphisms the 
sample size was small or absent limiting our power to detect small to medium effect sizes, 
given that we had 80% power to detect an odds ratio 1.92 for the SNP with the lowest 
minor allele frequency in the retrospective analyses, this was HR=3.00 for the prospective 
analyses. 
 Another concern relates to the retrospective collection of data. The assessment of a 
single episode MDD in retrospect may not be accurate. Though, our prospective data 
were not showing associations either.   
 In conclusion, although there is considerable evidence that these polymorphisms 
are associated with onset and presence of MDD no consistent associations of the GR and 
MR candidate gene polymorphisms with recurrence of MDD were found. To draw firmer 
conclusions, replication is needed preferably using a whole gene­based association analysis 
of SNPs on the GR and MR also including interactions with modulating and serotonergic 
genes. In this way, the complex pattern of interaction between environmental factors 
and genetic factors related to recurrence of MDD could be further unravelled.
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This thesis reports on several studies about the prevalence and predictors of recurrence 
of major depressive disorder based on data of the studies NEMESIS and NESDA. The aims 
of this thesis were to investigate the risk of recurrence of major depressive disorder across 
care settings and to study its predictors and the way these predictors interact. In this 
chapter, the main findings are summarized and discussed, and also methodological 
considerations and suggestions for future research are set out.  
7.1.  Summary
Major depressive disorder is highly prevalent and morbid. The high burden of MDD is in 
part due to its course, since chronicity and recurrence are frequent features of the 
condition. Major depressive disorder is a heterogeneous disorder and its aetiology involves 
a complex interplay between genetic and environmental factors which is not yet 
understood. Knowledge of predictors of recurrence of major depressive disorder 
recurrence predictors is essential for the development of prevention and treatment 
decisions. Over the past 20­30 years, a number of studies have investigated predictors of 
recurrence of major depressive disorder. However, no systematic literature review is 
available on prevalence and predictors, comparing patients in specialized care with those 
in primary care and community settings. In Chapter 2, a systematic literature review is 
presented. The overall conclusion is that the percentage of recurrence in specialized 
mental health care is very high (up to 85% after 15 years). Therefore, in this population it is 
more appropriate to ask when rather than whether the patient will experience a recurrence. 
The studies found that the percentage of recurrence in the primary care population is 
similar to that in specialized mental health care and is lower again in the general population 
(up to 35% after 15 years). Clinical factors (number of previous episodes and subclinical 
residual symptoms) appear to be the most important predictors of time to recurrence, 
whereas sociodemographic factors do not seem to play a role. It was concluded that data 
from studies performed in the general population and primary care on the recurrent 
course of major depressive disorder are scarce and prospective studies are lacking. Data 
on genetic risk factors and dysregulated neuro­endocrine parameters (HPA­axis) were not 
included in this review. In Chapter 3, the main predictors of recurrence of a major 
depressive disorder in the general population were investigated. It was concluded that 
the estimated cumulative percentage of recurrence of MDD was 42.0% by 20 years. 
Multivariably, younger age, higher number of previous episodes, a severe last depressive 
episode, negative youth experiences and ongoing difficulties are significant predictors of 
recurrence. Although the long­term risk of recurrence was high, the recurrence risk was 
lower than that found in clinical samples. Thus, subjects in the general population who 
have experienced a major depressive episode have a long­term vulnerability for 
recurrence. Factors predicting recurrence include illness­related and stress­related factors. 
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It was found that the risk of recurrence depended on the number of predictors present: 
after 10 years the cumulative recurrence percentage of MDD was 3.4% for respondents 
with no predictors, 19.0% for respondents with one predictor, 26.6% for those with two 
predictors, 56.5% for those with three predictors and 65.0% for those with four or more 
predictors. In Chapter 4, the time to recurrence of MDD and its predictors were studied in 
primary care and specialized mental health care. The main findings were that there was no 
significant difference in time to recurrence of MDD between subjects in specialized 
mental health care and those in primary care. In multivariable analyses, a family history of 
MDD and previous major depressive episodes were associated with a shorter time to 
recurrence. The predictors did not differ across treatment settings. In Chapter 5, it was 
investigated whether HPA­parameters were associated with time to recurrence of major 
depressive disorder. The study confirmed previous findings that a higher cortisol awakening 
response (CAR), related to the sensitivity of the HPA­axis, increased vulnerability to 
recurrence of MDD even if a subject had been in remission for a long period. Neither 
the dexamethasone test nor evening cortisol levels were associated with recurrence and 
the higher risk for recurrence related to a high CAR was not dependent on stressful life 
events. Finally in Chapter 6, the research focused on the association between poly­ 
morphisms of the glucocorticoid and mineralocorticoid receptor and the risk for 
recurrence. Recurrence of MDD was not associated with these polymorphisms and no 
interaction effects were found with stressful conditions.  
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7.2.  Discussion 
Recurrence risk
In Chapter 2, it was concluded that MDD is often a recurrent disorder with consequences 
over the entire lifespan. The risk of recurrence among subjects treated in general practice 
and specialized care settings seems to be comparable; at two­year follow­up 26.8% of 
subjects treated in primary care and 33.5% treated in specialized mental health care 
experienced recurrence of MDD after achieving remission for at least three months 
(Chapter 4). These percentages are in line with previous studies (Lin et al., 1998; Gopinath 
et al., 2007; Vuorilehto et al., 2009; Suija et al., 2011). It also appears that in the general 
population, subjects who have experienced an MDE have a long­term vulnerability for 
recurrence which could be triggered under certain circumstances (Chapter 3). A cumulative 
incidence of MDD recurrence of 42% was found. This percentage is higher in comparison 
with previous studies. This result is difficult to compare with other studies due to 
differences in duration of remission, follow­up, diagnosis and population. The study by 
Eaton et al. (2008) is the most similar to this study but included first incident cases only. 
This study found a recurrence rate of 35% after 23 years. 
Predictors of recurrence of MDD: comparison with first episode  
and chronic course 
In this thesis, several predictors of time to recurrence of MDD were found. In the general 
population (Chapter 3), younger age, higher number of previous episodes, a severe last 
depressive episode, negative youth experiences and ongoing difficulties were significant 
predictors of recurrence. The risk for recurrence was also higher in subjects with multiple 
risk factors. In patients treated for MDD in general practice and specialized mental health 
care (Chapter 4), family history was also a predictor of time to recurrence. These predictors 
have also been found in other studies (Solomon et al., 2000; Melartin et al., 2004; Gophinah 
et al., 2008) and did not differ across treatment settings (Chapter 4). Subclinical residual 
symptoms could not be taken into account in these studies because the data did not 
allow for such precision. However, in Chapter 2 (review) subclinical residual symptoms 
were one of the main risk factors. Moreover, in Chapter 5 was found that the cortisol 
awakening response was a predictor of recurrence. This result was also in line with previous 
studies (Ribeiro et al., 1993; Zobel et al., 1999; Harris et al., 2000; Zobel et al., 2001; Hatzinger 
et al., 2002; Appelhof et al., 2006; Aubry et al., 2007; Bhagwagar et al., 2008; Pintor et al., 
2009; Vrshek­Schallhorn et al., 2013). The results of this thesis (Chapter 2, 3 and 4) indicate 
that demographic determinants are not clear predictors for MDD recurrence, although in 
other studies was found that they play a role in the onset of the first depressive episode 
(de Graaf et al., 2002; de Graaf et al., 2013). Previous research with data from NEMESIS and 
NEMESIS­2 (de Graaf et al., 2002; de Graaf et al., 2013) concluded that first incidence of 
mood disorder (major depression, dysthymia and bipolar disorder) is associated with 
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female gender, low educational status, substantial decrease in income, no longer living 
with partner, negative life events, ongoing difficulties and a high level of neuroticism. 
Thus, it can be concluded that stress­related factors play a role in both incidence and 
recurrence. Additionally, clinical factors related to past MDD episodes (number of previous 
episodes, severity of the last episode) are prominent predictors for time to recurrence. 
Hence, past episodes predict future episodes. The predictors for recurrence and chronicity 
of MDD also show similarities. Using NEMESIS data, Spijker et al. (2004) found that 
determinants of persistence of MDD were severity of the index episode, longer duration 
of previous episodes, physical illness, including chronic physical illness, and lack of social 
support. For both courses, illness­related factors are important. Moreover, it is possible 
that chronicity and recurrence are both expressions of the same dimension given that ill­
ness­related factors are prominent predictors in recurrence and in a chronic course. 
Methodological considerations
Despite the use of strict selection criteria, the studies were difficult to compare in the 
systematic review (Chapter 2). This also explains why a formal meta­analysis was not 
performed. In Chapters 3 through 6, datasets from both NESDA and NEMESIS were used. 
Although both studies included a large sample, were prospective and included a large set 
of covariates, several limitations must be acknowledged. First, in NEMESIS (Chapter 3) and 
NESDA (Chapters 4 and 5), the last depressive episode was assessed in retrospect. It might 
be that the assessment for age of onset and recency of the last depressive episode have 
not been accurate. It is likely that this could have led to an overestimation of the time to 
recurrence and an underestimation of the number of recurrences. Secondly, in NESDA the 
recurrence risk was investigated across different treatment settings. The subjects treated 
in specialized mental health care were recently referred and, as a consequence, this 
sample is not representative of the entire population treated for MDD in specialized 
mental health care, since subjects with more severe, chronic or frequently recurring MDD 
are probably underrepresented. Therefore, the difference in recurrence risk between 
primary care and specialized mental health care could have been underestimated. On the 
other hand, there was no statistical difference in our study in the percentage of remission 
in primary care versus specialized mental health care. This suggests that both cohorts are 
comparable in this regard. Third, in both NEMESIS and NESDA, subclinical residual 
symptoms, which are a strong predictor of recurrence risk (Judd et al., 1998), could not be 
included in the analysis because the data did not allow for such precision. However, it is 
reasonable to assume that residual symptoms are more common in subjects treated in 
specialized mental health care than in those treated in primary care.
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Towards a model of risk
What research is needed?
The studies in this thesis assessed recurrence risk across settings and identified several 
predictors of recurrence. Important predictors for inclusion in a model of risk have 
probably been identified, it seems unlikely that new factors with a high predictive value 
will emerge in the near future. Although there is no use of the CAR, the increase of cortisol 
upon awakening, as a predictor in a clinical setting so far, it is a valuable instrument in 
research on stress­related disorders such as MDD. It remains to be seen whether a higher 
CAR is an epiphenomenon or plays a substantial role in the onset or course of a depressive 
episode. It could be hypothesized that a higher CAR reflects a marker for increased 
sensitivity for stress, including psychosocial stress, which is associated with an increased 
risk for recurrence. Although genetic factors hold promise, it is believed that many genes 
are involved and it is likely that individual genes only contribute a small percentage of the 
risk for recurrence of MDD. Chapter 6 did not find GR or MR polymorphisms associated 
with recurrence either. Understanding how predictors interact with one another is a major 
challenge. There may be specific interactions that raise the risk for recurrence. For example, 
a recent study by Wilson et al. (2014) found that individuals with both adolescent onset 
and recurrent episodes of MDD represented a particularly severe group with persistent 
psychosocial impairment in adulthood (Wilson et al., 2014). In this way, a specific high­risk 
profile could be identified. 
 To better understand the aetiology of recurrence of MDD, it is also advisable to 
measure different course variables (severity, time between recurrences, number of life­ 
time recurrences) because different factors could predict different courses (Conradi et al., 
2008). The influence of past episodes on risk is a major problem. Conducting research in 
this field is like shooting at a moving target. Keeping the long term vulnerability for 
recurrence of MDD in mind, this suggests that, to better understand aetiology of recurrence, 
future research must move to time­sensitive modelling techniques, e.g. structural equation 
modelling, incorporating multiple interacting factors across long periods of time (Beard 
et al., 2008; Colman et al., 2010). 
Predictors: scar versus trait
Given that recurrence of MDD contributes to risk for depression, it follows that either 
depression itself increases vulnerability to recurrence (scar­effect) or individuals at high 
risk for recurrence already possess certain vulnerability characteristics (trait­effect) (Burcusa 
& Iacono, 2007). This distinction is important because if the scar hypothesis is true, early 
intervention is key. It is likely that both scar and trait factors play a role. Our results (Chapter 
5) suggest that a high cortisol awakening response (CAR) may constitute a ‘trait’ marker for 
recurrence, whereas a lower CAR can be identified as a ‘scar’ marker for current depression 
(Vreeburg et al., 2013). This is in line with previous studies. Vrshek­Schallborn et al. (2013) 
concluded that a higher CAR predicted initial onset. Furthermore, the CAR is higher in 
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young people who have not experienced depression but have a family history of 
depression (Mannie et al., 2007; Vreeburg et al., 2010) which suggests a genetic vulnerability 
trait. A previous study (Wϋst et al., 2000) also concluded that there is a significant genetic 
influence on the CAR. However, no associations between GR and MR gene polymorphisms 
or interactions between GR and MR haplotypes, stressful conditions and recurrence of 
MDD were found in Chapter 6. Replication of this study using a fully gene­based 
association analysis of SNPs on the GR and MR is recommended. In this way, a better 
understanding of the complex pattern of interaction between environmental factors and 
genetic factors related to recurrence of MDD could be achieved.  
Identifying a high risk group for recurrence 
Nonetheless, with each recurrent depressive episode, the impact on symptoms and 
well­being appears to worsen (Roca et al., 2011). This highlights the need to intervene early 
to prevent future episodes. Thus, identification of high risk groups after the first episode is 
of particular importance (Monroe et al., 2011). Research should focus on individuals who 
recover after the first episode of MDD, as this could lead to the greatest health gains. 
Approximately 50% of those who recover after a first episode will experience a recurrence 
(APA, 2000). In other major psychiatric disorders, e.g. schizophrenia and bipolar disorder, 
early intervention is thought to prevent a protracted course (McGorry et al., 2006; Berk 
et al., 2010). This is also likely to be true for MDD, but research is still lacking. 
 Clinicians should not only classify depression into prodromal phase, first episode, 
residual symptoms after depression, recurrence or chronic course (Hetrick et al., 2008), but 
also perform a risk assessment for recurrence (short time to recurrence, multiple 
recurrences) after the first episode. It could be helpful to develop a short risk assessment 
tool for this purpose. Wang et al. (2014) was the first to develop a risk assessment tool for 
recurrence of MDD using a general population sample. This 19­item tool can be filled in by 
the individual via internet, has a reasonable predictive value (C­statistic=0.75) and is easy 
to use. The C­statistic was 0.59 when only the number of previous episodes was used in 
the model. This model has not yet been tested in treatment settings and was not 
developed to identify high risk groups for recurrence after the first episode, which should 
be the next step. As a minimum, the research model should contain the illness­related 
factors (severity of the MDD, subclinical residual symptoms) stress related factors 
(childhood trauma, life events, and ongoing difficulties), younger age and family history. 
Recommendations from the recent TRIPOD (transparent reporting of the multivariable 
prediction model for individual prognosis or diagnosis) statement (Collins et al., 2015) 
should be applied. Other disciplines in medicine have developed risk assessment tools. In 
cardiology, the application of risk assessment tools in daily practice has improved 
treatment of risk factors and reduced the risk for myocardial infarction substantially (Bata 
et al., 2000). Identification of individuals with a high risk profile and understanding of the 
type of interventions that are effective in preventing recurrences after the first episode 
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could form the basis for well­founded guidelines for treatment and recurrence prevention 
of MDD. Based on this knowledge, we could draw up an integrated model of risk. 
Implications for treatment decisions
Subjects with significant and multiple predictors for recurrence should be closely 
monitored and treatment strategies to prevent recurrence should be considered. The 
knowledge that clinical variables are significant predictors could be taken into account 
during the initial phase of treatment for depression. It would seem reasonable to treat 
frequent recurrences and residual symptoms as a chronic disorder (Andrews et al., 2001), 
whereas treatment for patients with a low risk of recurrence may be limited to the index 
episode. Subjects with a high risk for recurrence should receive maintenance treatment 
with antidepressants, with special attention to treatment adherence. The risk of relapse or 
recurrence for those undergoing maintenance treatment with antidepressants can be 
reduced by 25% compared with a placebo (Geddes et al., 2006; Kaymaz et al., 2008). 
However, the efficacy of antidepressants on the recurrence rate over a long period is 
unknown. Preventive psychotherapeutic interventions should also be considered in 
subjects with multiple recurrences, focusing on residual symptomatology and specific 
coping styles to improve resilience to stressful circumstances (Bockting et al., 2008). For 
recurrence prevention, it is also important to identify which predictors are causal, which 
predictors might change over time or therapy and in what way they interact (Kraemer, 
2001). A variable could be a proxy risk factor, a moderator, a mediator, be independent but 
also protective (Kraemer, 2001). As mentioned before, clinical risk factors are important 
predictors of recurrence, but most of these factors, apart from subclinical factors, lie in the 
past and cannot be changed. Programmes for depression recurrence prevention should 
focus on those risk factors that can be changed. For example, it is important to treat 
subclinical symptoms aggressively, alleviate ongoing difficulties where possible and 
improve coping strategies for dealing with stress. 
 The risk of recurrence in primary care is also considerable. Our results also imply that 
prevention of the recurrence  of MDD is advised for high­risk groups, not only in specialized 
mental health care, but also in primary care. Nowadays, subjects are more likely to be 
referred to specialized mental health care if they are younger, report suicidal symptoms, 
had chronic depression or are referred for psychotherapy (Piek et al., 2011). It could be that 
the need for acute treatment of MDD or the preferences of the patient play a greater role 
in decisions to refer to specialized care than expectations of a protracted course. This 
latter factor should also be taken into account. To improve the management of MDD 
recurrence prevention, collaborative care models are desirable (Katon et al., 2011), with 
long term management and enhanced communication between primary and specialized 
mental health care professionals across psychiatric services. Both general practitioners 
and specialized mental health care professionals should be aware of the main risk factors 
and recurrence prevention should be integrated across care settings.
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7.3.  Concluding remarks
Kraeplin wrote more than 90 years ago that he found it impossible to predict whether 
depression would be limited to one episode or an individual would experience further 
episodes (Kraeplin, 1921). Do we have a better understanding of recurrence of MDD today? 
Can we inform Miss C, who was introduced in the Introduction, better? Yes, we can. We 
can inform her that she has, unfortunately, a high risk for a recurrence due to previous 
episodes of depression, along with subclinical residual symptoms and a first degree family 
member with depression in the past. We could also advise her to turn to psychotherapy 
to diminish the risk of recurrence. While the main risk factors have probably been identified, 
their precise interactions are unknown. Prediction of time to recurrence after a first 
episode is a major challenge. This is likely to be the area in which the greatest health gains 
can be made. To that end, a risk assessment tool for recurrence should be further 
developed to distinguish those with and whose without a high risk for recurrence.
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Depressie is een heterogene aandoening met een hoge prevalantie en morbiditeit. De hoge 
ziektelast van depressie wordt gedeeltelijk veroorzaakt door het chronische en recidiverende 
beloop. De etiologie van depressie is complex waarbij zowel genetische­ als omgevings­
factoren een rol spelen. Het is van groot belang om de predictoren van recidivering te 
weten omdat deze kennis nodig is voor preventie van recidivering. In de afgelopen 20­30 
jaar hebben verschillende studies onderzoek gedaan naar de prevalentie en predictoren 
van recidivering. Er was tot nog toe hiervan geen systematisch overzichtsartikel gemaakt 
en met name was er geen vergeleking tussen de verschillende echelons (2e lijn, 1e lijn of 
algemene bevolking). In hoofstuk 2 is het overzichtsartikel weergegeven. De conclusie 
was dat het percentage van recidivering in de GGZ hoog is (tot 85% in 15 jaar) en dat het 
voor deze patiëntenpopulatie zinvoller is om een inschatting te maken wanneer dan of 
een patiënt een recidief zal krijgen. Verder werd geconcludeerd dat het recidiveringsrisico 
van depressie bij diegenen die door de huisarts behandeld worden vergelijkbaar is met 
patiënten die in de GGZ in behandeling zijn en dat het recidiveringsrisico in de algemene 
bevolking lager is (35% in 15 jaar). Klinische factoren (aantal eerdere episoden en 
subklinische restverschijnselen) zijn waarschijnlijk de meest belangrijke predictoren van 
tijd tot recidief en sociodemografische factoren zijn vermoedelijk niet geassocieerd met 
recidivering. Verder werd er geconcludeerd dat er slechts een beperkt aantal studies zijn 
verricht in de algemene bevolking en de eerste lijn en met name weinig prospectieve 
studies. In het overzichtsartikel zijn genetische en neuro­endocriene predictoren (HPA­as) 
niet onderzocht. In hoofdstuk 3 werden de predictoren in de algemene bevolking 
onderzocht. Het cumulatieve recidief percentage was 42.0% na 20 jaar. Uit multivariate 
analyses bleek dat jonge leeftijd, een hoog aantal eerdere episoden, een ernstiger laatste 
depressieve episode, traumatische jeugdervaringen en aanhoudende problemen significant 
predictoren waren voor recidief. In dit cohort was het recidief risico aanzienlijk maar lager 
in vergelijking met patiënten die behandeld worden in de eerste of tweede lijn. Dus ook 
individuen uit de algemene bevolking kunnen een langdurig risico hebben op een 
recidief en factoren die recidief voorspellen zijn vooral ziekte­ en stress gerelateerde 
factoren. Ook werd gevonden dat het risico op recidief afhing van het aantal risicofactoren 
dat een individu heeft; het cumulatieve recidief percentage na 10 jaar was 3.4% bij personen 
zonder de eerdere genoemde predictoren, 19.0% bij personen met 1 risicofactor, 26.6% 
bij personen met 2 predictoren, 56.5% voor diegenen met 3 predictoren en 65.0% bij 
diegenen met 4 of meer  predictoren. In hoofdstuk 4 werd tijd tot recidief van depressie 
en de betrokken predictoren onderzocht in de eerste en tweede lijn. Belangrijkste 
bevindingen waren dat er geen significant verschil was in tijd tot recidief tussen patiënten 
die in de GGZ en die in de eerste lijn werden behandeld. Bij multivariate analyse waren 
een positieve familie voorgeschiedenis voor depressie en eerdere episoden van depressie 
geassocieerd met tijd tot recidief. De predictoren verschilden niet per setting. In 
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hoofdstuk 5 werd onderzocht of HPA­as parameters geassocieerd waren met tijd tot 
recidief. Het onderzoek bevestigde eerder onderzoek dat een hogere cortisol ochtend 
curve, welke gerelateerd is aan de sensitiviteit van de HPA­as, de kwetsbaarheid voor een 
recidief verhoogd ook al is de depressie al lange tijd in remissie. De dexamethason 
suppressie test en avond cortisol waarden waren niet geassocieerd met recidief en het 
hogere risico bij een hoge cortisol ochtend curve was niet afhankelijk van ernstige levens­
gebeurtenissen. In hoofdstuk 6 werd onderzocht of polymorfismen van de glucocorticoïd 
en mineralocorticoïd receptor geassocieerd zijn met risico of recidief. Associaties werden 
niet gevonden en ook werden geen interacties met stress gerelateerde factoren gevonden. 
In hoofdstuk 7 werden de bevindingen en beperkingen van de studies besproken, de 
implicaties voor de praktijk belicht en werden suggesties gedaan voor verder onderzoek 
om te komen tot een beter begrip van recidivering van depressie. Een uitdaging zal zijn of 
personen met een hoog risico op recidivering na een eerste episode van depressie 
kunnen worden geïdentificeerd. Een risico taxatie instrument kan hierbij ondersteunend 
zijn. Zodoende kan met gerichte behandeling recidivering mogelijk verder voorkomen 
worden. 
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